ISPE Bordeaux Final CR/Bladen - International Society for ...

POSTER SESSIONS 

Guidelines 

OVERVIEW 

Poster sessions are designed to give presenters an opportunity to discuss informally their 

research with colleagues interested in their research. The purpose of the posters is to visually 

stimulate interest in the research, to present sufficient information for viewers to understand the 

methods, results, and significance of the research, and to promote conversations and networking 

among conference participants. 

POSTER SESSION SCHEDULE 

Posters will be displayed in the Bordeaux Conference Center Espace Pluriel. Each 

session is for one day; Session A – Monday, 23 August; Session B – Tuesday, 24 August; 

and Session C-Wednesday, 25 August. 

SET UP: 07:00 to 08:00 

All posters must be up by 08:00. 

OPEN: Espace Pluriel will be open: 08:00 to 17:00. 

DISCUSSION TIME: 

Presenters should be by posters between 12:00 and 13:30. 

EuroDURG, the European Drug Utilization Research Group, invites all poster presenters displaying 

their posters on Tuesday, August 24 (Session B), to participate in the EuroDURG Poster Walk. 

EuroDURG will offer presenters the opportunity to present their work and to discus their results 

with an audience. Presenters shoud be at their posters between 12:15 and 13:15. When the 

poster walk chair and audience stops at your poster, please give a brief, 3-minutes, presentation 

and to answer questions about your research. EuroDURG will grant a ‘Best Poster Award’, offering 

the winner free registration for the UK-EuroDURG meeting in Northern Ireland in 2005. All 

meeting participants are invited to join in the walk. 

TAKE DOWN: All posters must be taken down by 18:45 on Monday & Tuesday, and by 17:30 on 

Wednesday. NOTE: Neither ISPE or the Bordeaux Conference Center will be responsible for any 

poster that is left up overnight or is lost or damaged. 

NUMBERING SYSTEM 

Each poster board will be numbered. The poster number is the first number listed in the 

final program. Presenters should attach their posters to the board number corresponding 

to the number assigned to their poster in the final program, which will be available at the 

registration desk. The abstract number, for use in locating abstracts in the final program 

and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [xxx] 

after the title of the abstract. 

POSTER SPECIFICATIONS 

1. Posters must be designed to fit a freestanding poster board 0,93 meters wide by 1,63 meters 

high (approximately 3’1”wide by 5’4” high). This board will be the only support device 

available. Business cards or small leaflet literature for distribution may be inserted in an 

envelope and affixed to the board. Poster orientation: Portrait 

2. Posters may be attached to the boards by pushpins or Velcro. Please bring your own mounting 

supplies. 

28 

20th International Conference on Pharmacoepidemiology 

& Therapeutic Risk Management

POSTER SESSION A • MONDAY, 23 AUGUST, 2004 

1 Accuracy of Ramq Medical Services Claims 

To Identify Episodes of Hospitalizations for 

Patients with Upper Gastrointestinal 

Bleeding: A Data Validation Study [79] 

Amir Abbas Tahami Monfared, Elham Rahme, 

Jacques LeLorier. (Canada) 

2 Validity of the General Practice Research 

Database: A Systematic Review [80] 

W Marieke Schoonen, Andrew J Hall. 

(United Kingdom) 

3 An Algorithm To Extract Medical Codes for 

Diagnoses from Unstructured Free Text 

Recorded by General Practitioners in the 

UK [81] 

Anoop D Shah, Carlos Martinez. 


4 Disease Comorbidities and Their Pattern of 

Co-Occurrence Using Practice-Recorded 

Database: A Cluster Analysis Approach [82] 

Maurille Feudjo-Tepie, Neil S Roskell, John W 

Logie, Monika Stender. (United Kingdom) 

5 A Systematic Approach for Describing 

Comorbidities Using the UK General 

Practice Research Database [83] 

Neil S Roskell, John W Logie, Monika Stender, 

Maurille Feudjo-Tepie. (United Kingdom) 

6 The Validity of Electronic Precription 

Claims Records: A Comparison of Electronic 

PBM Claims Records with Pharmacy 

Provider Derived Records [84] 

Bradley C Martin, Emily R Cox. (United States) 

7 The New Generation Pregnancy Exposure 

Registries [85] 

Deborah L Covington, Peggy A Doi, Melisse 

Baylor, Hugh Tilson. (United States) 

8 Comparison of Different Methods To 

Calculate Persistence of Drug Use by Using 

Pharmacy Records [86] 

Boris LG Van Wijk, Olaf H Klungel, Eibert R 

Heerdink, Anthonius de Boer. (Netherlands) 

9 Recent Evidence Surrounding the Efficacy 

of Protected Carotid Angioplasty with 

Stents [87] 

Kirsteen R Burton, Thomas Lindsay. (Canada) 

10 Accuracy of Inpatient Cardiovascular 

Diagnoses in a Saskatchewan Health 

Database [88] 

Suellen M Curkendall, Mary Rose Stang, 

Judith K Jones, Jean T Barbey, Earl Goehring, 

Stephan Lanes, Cynthia de Luise. (United States) 

11 Did Heat Wave Modify Efficacy of Drugs 

Prescribed in Patients with Dysautonomia- 

Related Orthostatic Hypotension during 

Summer 2003 in France? [89] 

Atul Pathak, Maryse Lapeyre-Mestre, Jean-Louis 

Montastruc, Jean-Michel Senard. (France) 

12 Prognosis of Patients with Atherothrombotic 

Disease: A Prospective Survey in Non Hospital 

Setting [90] 

Alain Leizorovicz, Jean Pierre Cambou, Marie 

Annick Herrman, Jean Ferrieres. (France) 

13 Maintenance of Sinus Rhythm in Patients 

with Atrial Fibrillation: Safety of Flecainide 

IR and Predictors of Relapses. Epiflec 1 

Study [91] 

T Simon, M Mary-Krause, M Thuault, A 

Chatelin, M Gouin, P Jaillon. (France) 

14 Non-Compliance with Antihypertensive 

Drugs Is Associated with Discontinuation of 

Antihypertensive Drugs [92] 

Boris LG van Wijk, Olaf H Klungel, Eibert R 

Heerdink, Anthonius de Boer. (Netherlands) 

15 QTc Prolongation in a Healthy Elderly 

Population and the Risk of Sudden Cardiac 

Death [93] 

Sabine MJM Straus, Gysele S Bleumink, 

Cornelis S van der Hooft, Marieke L de Bruin, 

Jan A Kors, A Hofman, Jacqueline CM 

Witteman, Bruno HCh Stricker. (Netherlands) 

16 Atorvastatin Seems To Perform Better in the 

Prevention of Cardiovascular Events Than 

Other Statins [94] 

Jacobus T van Wyk, Jeanne P Dieleman, 

Hans Dunselman, Marc AM van Wijk, Miriam 

CJM Sturkenboom. (Netherlands) 

17 The Incidence of Ventricular Fibrillation 

and Ventricular Tachycardia in a Primary 

Care Population [95] 

Gwenda Hughes, Stephan Rietbrock, Christoph 

Reiter, Carlos Martinez. (United Kingdom) 

18 Cox-2 Selective Inhibitors and 

Cardiovascular Outcomes in an Elderly 

Population [96] 

Linda Levesque, James M Brophy, Bin Zhang, 

Chantal Bourgault. (Canada) 

19 Changes in Blood Pressure Lowering 

Treatment: Do We Reach Treatment Goals? 

The Tromso Study 1994 AND 2001 [97] 

Anne Elise Eggen, Kristin Svanquist, Inger 

Njolstad, Frode Skjold. (Norway) 

20 Prevalence of Congestive Heart Failure 

within a Large US Health Insurance 

Database Using Claims [98] 

Patricia Mona Eng, Kelly Oh, Jennifer Cutone, 

Dan Fife, Jeff Linder, John Seeger. (United States) 

21 Post-Marketing Surveillance for the Safety 

and Efficacy of Cilnidipine in Patients with 

Hypertension [99] 

Young Sik Kim, Sung Sunwoo, Hye Ree Lee, 

Yoo Seock Cheong, Sang Yeoup Lee, Joo Sung 

Park, Minkwan Rho, Chang Won Won, Korea 

Post-Marketing Surveillance Research Group. 

(Republic of Korea) 

22 Improved Discharge Planning Following 

Congestive Heart Failure or Myocardial 

Infarction Hospitalization Using 

Computerized Physician Order Entry [100] 

Marie R Griffin, Javed Butler, Patrick G 

Arbogast, Theodore Speroff, Lemuel R 

Waitman, Martha Newton, Wayne A Ray. 

(United States) 

23 Over-the-Counter Analgesics’ in 

Ambulatory Pharmacies - Availability and 

Affordability [101] 

Ilko N Getov, Roza E Evtimova, Zlatka D 

Dimitrova. (Bulgaria) 

24 A Preliminary Study into Pain Perception 

and Analgesic Usage by Young People [102] 

Ilse Truter. (South Africa) 

25 Differences in Use of Non-Prescription 

Analgesics among Young People with 

Norwegian and Immigrant Background [103] 

Asgeir Amundsen, Kari Furu, Elin Olaug 

Rosvold, Espen Bjertness, Svetlana Skurtveit. 

(Norway) 

26 Inhaled Corticosteroids (ICS) and the Risk 

of Fractures in Children and Adolescents [104] 

Raymond G Schlienger, Susan S Jick, 

Christoph R Meier. (Switzerland) 

27 Safety and Appropriateness of Use of a Low 

Dose OTC Analgesic: Methodological Issues 

and Results of a Pharmacy-Based Cohort 

Study [105] 

Joerg Hasford, Nicholas Moore, Kjetil Hoye, 

Ch Milliet, Markus Unkauf, J Magnette. 

(Germany) 

28 Inadequate Prevention of NSAID-Induced 

Gastrointestinal Events among Long-Term 

Users of NSAIDs [106] 

Ron MC Herings, Wim G Goettsch. 

(Netherlands) 

29 The Risk of Upper Gastrointestinal Tract 

Bleeding Associated with Mefenamic Acid 

in Women of Reproductive Age [107] 

Daniel I Mines, Laura A Novelli. (United States) 

30 Risk of Psychiatric Disorder after 

Paracetamol Poisoning [108] 

Peter Jepsen, Preben B Mortensen, Bente 

Norgård, Esben Agerbo, Ping Qin, Hendrik 

Vilstrup, Henrik T Sorensen. (Denmark) 

31 Patterns and Predictors of Prescription 

Narcotic Use among Selected Groups of 

Patients with Chronic Pain [109] 

Daniel H Solomon, Til Sturmer, Philipp S Wang, 

George Vaillant, Jerry Avorn. (United States) 

32 Non-Steroidal Anti-Inflammatory Drugs and 

Co-Prescriptions with Gastrointestinal Drugs in 

Osteoarthritis Patients: A Retrospective 

Cohort Study [110] 

Giampiero Mazzaglia, Claudio Cricelli, Mriam 

C Sturkenboom, Pierfrancesco Ruffo, Stefano 

Giovannoni, Ovidio Brignoli, Achille P Caputi. 

(Italy) 

33 Diclofenac Sodium Induced Sciatic Nerve 

Damage, a Pharmacoepidemiologic 

Approach [111] 

Gloria Shalviri, Kheirollah Gholami, Majid 

Cheraghali, Elahe Kamali, Nazanin 

Daryabaree. (Islamic Republic of Iran) 

34 New Guidelines for Tramadol Usage 

Following ADRs Reported to Iranian 

Pharmacovigilance Center [112] 

Kheirollah Gholami, Gloria Shalviri, Elahe 

Kamali, Nazanin Daryabari, Aida Zarbakhsh. 

(Islamic Republic of Iran) 

22-25 August 2004 Bordeaux Convention Center, France 

✒ 

29


30 

35 Quality of Non-Steroidal Anti-Inflammatory 

Drugs Prescription in the Ambulatory 

Service in Taiwan [113] 

Yea-Huei Kao Yang, Shu-Wen Jia, Shih-Chen Kuo. 

(Taiwan) 

36 First Line Pharmacotherapy Preferences 

among Turkish General Practitioners in 

Pain Management [114] 

Sinem Ezgi Gulmez, Hakan Ergun, Faik 

Cankat Tulunay. (Turkey) 

37 The Risk Benefit Profile of Non-Steroidal 

Anti-Inflammatory Drugs (NSAIDs) as 

Chemopreventives of Lung Cancer [115] 

Dayin Koompalum, Jeffery A Kotzan, Paul M 

Dainer, Anand N Vidyashankar, Luke P 

Naeher, Bradley C Martin. (United States) 

38 Undesirable Effects Related with Non- 

Steroidal Anti-Inflammatory Drugs by the 

Patients of Portuguese Community 

Pharmacies [116] 

Ermelindo Fontes, Helder Mota-Filipe, Ana 

Paula Martins. (Portugal) 

39 Cumulative Analgesic Use and Risk of 

Incident Hypertension in Men [117] 

Tobias Kurth, Til Sturmer, Robert J Glynn, 

Howard D Sesso, Julie E Buring, J Michael 

Gaziano. (United States) 

40 Liver Disease Associated with Allopurinol: 

Clinical and Immunological Studies in 7 

Cases [118] 

Vasco AJ Maria, Adriana Albuquerque, Rui 

MM Victorino. (Portugal) 

41 Does Mis-Specified Functional Form of a 

Continuous Variable in Building a 

Propensity Score Matter? [119] 

Kate L Lapane, Sherry Weitzen. 


42 Comparing Analytic Strategies Using 

Propensity and Disease Risk Scores: The 

Example of Nonsteroidal Antiinflammatory 

Drugs (NSAID) and Short-Term Mortality in 

the Elderly [120] 

Til Sturmer, Sebastian Schneeweiss, Alan M 

Brookhart, Kenneth J Rothman, Jerry Avorn, 

Robert J Glynn. (United States) 

43 Identifying Patients with Medication Errors 

Using the QRESEARCH Database [121] 

Anthony J Avery, Julia Hippisley-Cox, Ronan 

Ryan, Sarah Armstrong, Caroline J Morris, 

Judith A Cantrill. (United Kingdom) 

44 Pitfalls in Drug Management Systems and 

Quality of Anti-Tuberculosis Drug in Lower 

Southern Thailand [122] 

Korngamon Rookkapan, Virasakdi 

Chongsuvivatwong, Srirat Kasiwong, Saijai 

Pariyawatee, Yuthichai Kasetcharoen, 

Petchawan Pungrassami. (Thailand) 

45 Trends in Antimicrobials Consumption in a 

Multi-Profile Hospital in Belarus and 

Underlying Financial Influences [123] 

Maksim N Mily, Irina M Samsonova, Vladimir 

Y Lugovoy, Sergey A Golubev. (Sweden) 

46 Systematic Reporting of Adverse Events 

Associated with Highly Active Antiretroviral 

Therapy (HAART) in Human 

Immunodeficiency Virus (HIV)-Infected 

Patients: First Results of a Cooperative 

Study between the Pharmacovigilance 

Centre and the Department of Infectious 

Diseases in Reims, 2002-2003 [124] 

Aurelie Molia, Jean-Luc Berger, Christophe 

Strady, Anne Waldner, Isabelle Beguinot, 

Christine Rouger, Marie-Laure Germain, 

Thierry Trenque. (France) 

47 Concept of Defined Daily Dose Used for 

Follow-Up of Hospital Antibiotic 

Consumption [125] 

Agnes Sommet, Blandine Juillard-Condat, 

Magalie Baudrant, Philippe Cestac, Maryse 

Lapyre-Mestre. (France) 

48 Evaluation of Total Adipose Mass in HIV 

Patients Treated by Protease Inhibitors and/or 

Nucleosidics Analogs [126] 

Neda Tavassoli, Haleh Bagheri, Jean-Louis 

Montastruc, Jacques Bernard. (France) 

49 Antimicrobial Prescribing in Hospitalized 

Pediatric Patients: A Cross-National 

Comparison between Marburg (Germany) 

and Rijeka (Croatia) [127] 

Mike Ufer, Nives Radosevic, Anne Vogt, Goran 

Palcevski, Igor Francetic, Hanns J Seyberth, 

Vladimir Ahel, Vera Vlahovic. (Sweden) 

50 Antimicrobial Prescribing at a University 

Hospital: Justified or “Just in Case”. Testing 

a New Scoring System as a Key Quality 

Indicator [128] 

Vera Vlahovic-Palcevski, Igor Francetic, Goran 

Palcevski, Srdan Novak, Ulf Bergman. (Croatia) 

51 Study of HCV and HBV Infection on 

Antiretroviral Drug Safety in HIV Patients 

[129] 

Emmanuelle Guitton, Jean-Louis Montastruc, 

Haleh Bagheri, Maryse Lapeyre-Mestre. (France) 

52 Factors Associated with Self Reported 

Adverse Events That Have a High or Very 

High Impact on Every Day Life [130] 

Emmanuelle Guitton, Emmanuel Trenado, 

Maryse Lapeyre-Mestre. (France) 

53 Exploratory Study Using a Record-Linkage 

Database To Examine Drug Safety in 

Australia, with Cefaclor as an Example [131] 

John E Marley, Justin J Beilby, Don C Walker, 

Katherine M Duszynski, Nicole L Pratt, Ian W 

Boyd, John McEwen. (Australia) 

54 A Survey on Drug Utilization Pattern in the 

Health Care System of India [132] 

Bhagirath K Patel, Mukesh B Nandve, Ramesh 

K Goyal, Paresh B Shah. (India) 

55 Risk of Miscarriage for Pregnant Users of 

Pivmecillinnam [133] 

Mette V Skriver, Mette Norgaard, Lars 

Pedersen, Henrik T Sorensen. (Denmark) 

56 Influence of the Antibiotic Utilization on 

the Occurence of Vancomycin-Resistant 

Enterococci [134] 

Karel Urbanek, Milan Kolar. (Czech Republic) 


& Therapeutic Risk Management 

57 Use of Antimicrobial Surgical Prophylaxis in 

the Surgical, Gynecologic and Obstetric 

Interventions of a General Hospital [135] 

Luis E Salazar Domínguez, Elio M Rosete 

Gamboa, Juan A Furones Mourelles, Lino 

Aboy Capote. (Cuba) 

58 Observational Study on Length of Stay 

(LOS) and Cost of Antibiotic (AB) 

Medication in Chronic Obstructive 

Pulmonary Disease (COPD) Hospital Stays 

[136] 

Peter Verplanken, Philippe B Van Wilder. 

(Belgium) 

59 Analysis of Antibiotic Use in Belgian 

Hospitals Using the Minimum Basic Data 

Set (MBDS) [137] 

Philippe B Van Wilder, Peter Verplanken. 

(Belgium) 

60 Real Use of Anti-Infectives during 

Ambulant Care in the Federal Republic of 

Germany Since 1984 - Results of All 

Pharmacoepidemiological Surveys of the 

Former Federal Health Office (BGA) and the 

Robert Koch-Institute - [138] 

Hans-Ulrich W Melchert, Hildtraud Knopf, 

Ellen Pabel, Marianne Braemer-Hauth. 

(Germany) 

61 Trimethoprim-Sulphamethoxazole Induced 

Hepatitis: Evidence for an Immunological 

Mechanism [139] 

Vasco AJ Maria, Adriana Albuquerque, Rui 

MM Victorino. (Portugal) 

62 Antibiotics Use in South Western France 

Hospitals [140] 

Anne-Marie Rogues, Catherine Dumartin, 

Pierre Parneix, Nicole Marty, Jean-Claude 

Labadie, Jean-Pierre Gachie. (France) 

63 Risk Factors of Neuropathy during 

Rheumatoid Arthritis Treatment with 

Leflunomide [141] 

Karin Martin, Fabrice Bentaberry, Chantal 

Dumoulin, Ghada Miremont-Salamé, Joël 

Dehais, Thierry Schaeverbeke, Françoise 

Haramburu. (France) 

64 Management of Chronic Myeloid Leukemia 

in France: A Multicentric Cross-Sectional 

Survey on 538 Patients [142] 

Sophie Tardieu, Catherine Brun-Strang, Patrice 

Berthaud, Michalet Mauricette, Francois 

Guilhot, Philippe Rousselot, Roland Sambuc. 

(France) 

65 Prescription Patterns of Leflunomide in 

Rheumatoid Arthritis: Clinical Trials 

Compared with Actual Practice [143] 

Karin Martin, Fabrice Bentaberry, Chantal 

Dumoulin, Joël Dehais, Françoise Haramburu, 

Thierry Schaeberbeke, Bernard Bégaud. 

(France, Metropolitan) 

66 Evaluation of the UK Clozaril® Patient 

Monitoring System (CPMS) in the 

Prevention of Clozaril/Leponex Induced 

White Blood Cell Count Decline [144] 

Javier Cid Ruzafa, Ana M Rueda de Castro, 

Branderley Claudio, Chris D Andrews, 

O’Sullivan P Des. (Spain)


67 Follow-Up of a Pharmacovigilance Study in 

Psychiatry Involving TDM and 

Pharmacogenetic Testing [145] 

Eveline E Jaquenoud Sirot, Chin B Eap, Pierre 

Baumann. (Switzerland) 

68 French General Practitioners Management 

of Depression [146] 

François Liard, Thierry Labarthe, Isabelle 

Gasquet, Sophie Tardieu, Nathalie Joannard, 

Patrik Blin. (France) 

69 Increasing Use of Antipsychotics for 

Behavioral Indications in Children [147] 

William O Cooper, Gerald B Hickson, D 

Catherine Fuchs, Patrick G Arbogast, Wayne 

A Ray. (United States) 

70 The Association between Bone Mineral 

Density and the Use of CNS Active 

Medications [148] 

Mitsuyo Kinjo, Soko Setoguchi, Sebastian 

Schneewiess, Daniel H Solomon. (Japan) 

71 Cost-Effectiveness of Donepezil Therapy of 

Alzheimer’s Disease in Japan. Results of a 

40-year Simulation Study [149] 

Shunya Ikeda, Mia Kobayashi, Naoki Ikegami. 

(Japan) 

72 Comparison of Incidence Rates of 

Cerebrovascular Accident and Stroke 

Associated Events for Patients Prescribed 

Risperidone, Quetiapine and Olanzapine in 

General Practice in England: Results of a 

Retrospective Analysis of Prescription-Event 

Monitoring (PEM) Data [150] 

Deborah Layton, Scott Harris, Andrea Clarke, 

Lynda V Wilton, Saad AW Shakir. 


73 SSRI Use in Dutch, German and United 

States’ Youths: Cause for Concern? [151] 

Julie M Zito, Joerg Fegert, Lolkje van den Berg. 


74 Factors Associated with Dependence to 

Psychoactive Drugs in a Cohort of French 

Workers [152] 

Bienvenu T Ngoundo, Michel Niezborala, 

Dominique Briand-Vincens, Pierre Jansou, 

Evelyne Chastan, Jean-Louis Montastruc, 


75 Price Difference of Antipsychotic Drugs in 

Asia [153] 

Ataru Igarashi, Tsutani Kiichiro, Takashi 

Fukuda, Naotaka Shinfuku, Senta Fujii. (Japan) 

76 Psychotropic Drugs Use in France: Results 

from the European Study of Epidemiology of 

Mental Disorders (ESEMED /MHEDEA 2000) 

[154] 

Isabelle I Gasquet, Laurence L Negre-Pages, 

Annie A Fourrier, Viviane V Kovess, Jean 

Pierre JP Lepine. (France) 

77 Psychosocial Factors at Work and 

Psychoactive Drug Use among Workers: 

Gender Differences [155] 

Bienvenu T Ngoundo, Michel Niezborala, 

Jean-Louis Montastruc, Maryse Lapeyre- 

Mestre. (France) 

78 Anxiolytics and Hypnotics Benzodiazepines 

Deliveries for the Very Elderly in a French 

Region [156] 

Fanny Romain, Xavier Thirion, Vincent 

Pradel, Alain Masut, Carine Saillard, Julien 

Mancini, Christine Coudert, Joëlle Micallef. 

(France) 

79 Weight Change in Ziprasidone and 

Risperidone Treatment: Randomized Single 

Blind Multicenter Trial [157] 

Seung-Mi Lee, Yooni Kim, Nam-Kyung Choi, 

Hwa-Jung Kim, Yong-Sik Kim, Byung-Joo Park. 

(Korea) 

80 Acute Pancreatitis and Serotonin Specific 

Reuptake Inhibitors - A Signal To Evaluate 

Further [158] 

Anders Sundström, Sjölin-Forsberg Gunilla, 

Wiholm Bengt-Erik. (Sweden) 

81 Which Factors Influence Prescription to 

Depressed Patients? Comparison between 

Community Psychiatrists and General 

Practitioners [159] 

Sophie Tardieu, Isabelle Gasquet, Alain 

Bottero, Alain Gerard, Thierry Labarthe, 

Francois Liard, Patrick Blin, Michael Bohbot, 

Thierry Marquet, Sylvia Goni. (France) 

82 Cost-Effectiveness Analysis of Atypical 

Antispychotics in Schizophrenia [160] 

Dan Cooper, Jocelyne Moisan, Michel Gaudet, 

Belkacem Abdous, Jean-Pierre Gregoire. 

(Canada) 

83 Characterizations of Benzodiazepine 

Prescriptions in Veteran Patients [161] 

John A Hermos, Melissa M Young, Margaret R 

Stedman, David R Gagnon, Louis D Fiore. 


84 Oral Anti-Spastic Drugs in Non-Progressive 

Neurological Diseases: A Systematic Review 

[162] 

Eva Montane, Antoni Vallano, Joan-Ramon 

Laporte. (Spain) 

85 Sudden Unexpected Death (SUDEP) in 

Children and Adolescents with Epilepsy [163] 

Yingfen Hsia, Corinne S de Vries. 


86 Patterns of Psychotropic Drug Use in Young 

Children (Less Than 6 Years): Data from the 

Social Security Database of Aquitaine, South- 

Western France [164] 

Laurie Lévy, Annie Fourrier-Réglat, Philippe 

Latry, Nathalie Lechevallier, Corinne Martin- 

Guehl. (France) 

87 Do Depressed Patients Who Are Given 

Guideline Concordant Pharmacotherapy Use 

More or Less Health Services? [165] 

Maida J Sewitch, Regis Blais, Elham Rahme, 

Sophie Galarneau, Brian Bexton. (Canada) 

88 Determinants of Guideline Concordant 

Pharmacotherapy in Adolescents Diagnosed 

with Depressive Disorders [166] 

Maida J Sewitch, Regis Blais, Elham Rahme, 

Brian Bexton, Sophie Galarneau. (Canada) 

89 Supportive Behaviour in Working 

Environment: Patterns of Drug Use in a 

Sample of 2106 Workers in Southwestern 

France [167] 

Maryse Lapeyre-Mestre, Bienvenu T Ngoundo, 

Michel Niezborala, Dominique Briand- 

Vincens, Pierre Jansou, Evelyne Chastan, 

Jean-Louis Montastruc. (France) 

90 A Long Term Follow-Up Study of Patients 

Treated by Buprenorphine as a Maintenance 

Treatment for Opiate Dependence: A Study 

Using Data from the French Insurance 

System Prescription Database [168] 

Maryse Lapeyre-Mestre, Mireille Gony, Anne- 

Marie Navel, Jacques Bez, Jean-Louis 

Montastruc. (France) 

91 Is Rational the Present Polypharmacy of 

Psychiatric Patients? [169] 

Carlos De Las Cuevas, Emilio J Sanz. (Spain) 

92 The Pattern of Antipsychotic Drugs 

Coprescribing in Psychiatric Hospital in 

Belgrade [170] 

Nevena V Divac, Ranka Samardzic, Miroslava 

Jasovic-Gasic, Milica P Bajcetic. (Yugoslavia) 

93 Development of a National System for Drug 

of Abuse Monitoring: Results of the Osiap 

Survey (Ordonnances Suspectes Indicateur 

d’Abus et de Pharmacodependance) [171] 

Maryse Lapeyre-Mestre, Isabelle Lacroix, 

Francoise Haramburu, Valerie Auclair, Michel 

Mallaret, Nathalie Bernard, Jocelyne Arditti, 

Catherine Armand-Malaplatte, Caroline 

Vigneau, Martine Assouly, Marie-Christine 

Perault. (France) 

94 Recruitment of Parents and Doctors of 

Stimulant-Using Children Via Community 

Pharmacies [172] 

Adrianne Faber, Luuk J Kalverdijk, Lolkje TW 

de Jong-van den Berg, Ruud B Minderaa, 

Hilde Tobi. (Netherlands) 

95 The Use of Stimulants and Co-Prescribed 

Psychotropic Medication among Children in 

the Netherlands from 2000 to 2002 [173] 

Adrianne Faber, Hilde Tobi, Lolkje TW de 

Jong - van den Berg. (Netherlands) 

96 Sertindole Reduces Health Care Resource 

Consumption in Schizophrenia: Results of a 

Mirror Study [174] 

Christophe Sapin, Jean-Michel Azorin, Agathe 

Le Lay, Karina Hansen. (France) 

97 Benzodiazepine Prescribing and Patient Age 

[175] 

Therese E Kairuz, Ilse Truter. (South Africa) 

98 Prescribing of Anti-Migraine Agents in a 

South African Patient Setting [176] 


99 Methylphenidate: Prescribing Patterns in 

South Africa [177] 


22-25 August 2004 Bordeaux Convention Center, France 31 

✒


100 Paterns and Frequency of Atypical 

Antipsychotic Drugs[Apos] Prescribing in 

French Psychiatric Medical Centers [178] 

Thierno Diatta, Sylvie Blazejewski, Ariane 

Quesnot, Severine Lignot, Arnaud Portier, 

Myriam Bouhassira, Annie Fourrier. (France) 

101 Parents’Attitudes and 

Psychopharmacological Treatment of 

Children [179] 

Hilde Tobi, Luuk J Kalverdijk, Hillegonde 

Nusse, Ruud B Minderaa. (Netherlands) 

102 Are Methylphenidate Users Insured under a 

Private Drug Plan Similar to Those Users 

Insured under a Public Drug Plan? [180] 

Melanie St-Onge, Jocelyne Moisan, Andre 

Simpson, Suzanne Gingras. (Canada) 

103 Impact of Substance Use on the Seriousness 

of Parasuicide [181] 

Marie Tournier, Mathieu Molimard, Abdelilah 

Abouelfath, Audrey Cougnard, Annie Fourrier, 

Hélène Verdoux. (France, Metropolitan) 

104 Antiepileptic Drug Utilization in the 

General Population in Italy [182] 

Nicola Vanacore, Giuseppe Traversa, Roberto 

Da Cas, Mariangela Rossi. (Italy) 

105 How Should Antidepressant Drug Effects Be 

Reported? [183] 

Ivar Aursnes. (Norway) 

106 Are Children and Youths with Attention- 

Deficit/Hyperactivity Disorder Accident 

Prone? [184] 

Elke Scharnetzky, Walter Schill, Gerd Glaeske, 

Katrin Janhsen. (Germany) 

107 Safety of Acetylcholinesterase Inhibitors in 

Alzheimer’s Disease. Experience from the 

Italian Cronos Study [185] 

Marina Maggini, Roberto Raschetti, Giacoma 

Carla Sorrentino, Bruno Caffari, Nicola 

Vanacore. (Italy) 

108 Incidence of Fractures among Epilepsy 

Patients: A Cohort Study in the General 

Practice Research Database [186] 

Patrick C Souverein, David J Webb, 

Hans L Petri, Tjeerd P van Staa, 

Toine CG Egberts. (Netherlands) 

109 Polypsychopharmacy in Schizophrenia In- 

Patients [187] 

Shu-yu Yang, Mian-Yoon Chong, Yea-Huei Kao 

Yang. (Taiwan) 

110 Drug Prescribing by Dutch Child and 

Adolescent Psychiatrists [188] 

Jacqueline G Hugtenburg, Eibert R Heerdink, 

Antoine CG Egberts. (Netherlands) 

111 The European Schizophrenia Cohort 

(EuroSC): Description and Preliminary 

Findings [189] 

Paul Bebbington, Matthias C Angermeyer, Jean- 

Michel Azorin, Traolach Brugha, Mondher 

Toumi. (France) 

112 Characteristics of Spontaneous Reporting 

Concerning Drug Abuse or Dependence: 

Analysis of Data Collected Via the NotS 

System by a French Ceip [190] 

Maryline Desplas, Isabelle Lacroix, Christine 

Damase-Michel, Jean-Louis Montastruc, 


113 SCoP Study (Sertindole Cohort: Prospective 

Study): Sertindole Versus Risperidone 

Outcome Study [191] 

Patrice Verpillat, Aurélia Mittoux, Peter 

Schuck, Frank Kuhn, Lowijs Perquin, Jozef 

Peuskens. (France) 

114 Meta-Analysis of Remission Rates of 

Escitalopram in the Treatment of Major 

Depressive Disorder Ijn Primary Care [192] 

Thomas R Einarson. (Canada) 

115 Cholinesterase Inhibitors and Liver 

Disorders: Safety Profile Analysis in the 

FDA SRS/AERS Database [193] 

Javier Cid Ruzafa, Carles Blanch, Ana M 

Rueda de Castro, Barbara A Warner. (Spain) 

116 The Feasibility of GP Pb-IIIa Antagonists 

Use in the Treatment of Patients with Acute 

Coronary Syndrome in the Department of 

Internal Medicine [194] 

Zaher S Azzam, Elias Sa’ad, Amal Jabarin, Oron 

Eilam, Norberto Krivoy. (Israel) 

117 Evaluation of African Traditional 

Management of Hypertension in the Nelson 

Mandela Metropole, South Africa [195] 

Mbali Z Luvuno, Maryna Van De Venter, Ilse 

Truter, Mea Van Huyssteen. (South Africa) 

118 Therapeutic Taditions and Compliance to 

Guidelines When Prescribing HMG-CoA 

Reductase Inhibitors [196] 

Henrik Ohlsson, Juan Merlo, Ulf Lindblad, 

Thor Lithman, Dennis Noreen, Bodil Ericsson. 

(Sweden) 

119 Declined Presentation 

120 Evidence for Inequalities in the 

Management of Coronary Heart Disease in 

Scotland [198] 

Colin R Simpson, Philip C Hannaford, 

David JP Williams. (United Kingdom) 

121 Rct Findings, Promotional Expenditures, 

and Prescribing Behavior: The Case of 

Doxazosin [199] 

Giuseppe Traversa, Roberto Da Cas, 

Clara Bianchi, Carlo Romagnoli. (Italy) 

122 A Multilevel Model for Statin 

Discontinuation and Switching Using a 

Large Prescribing Database [200] 

Nicola Fitz-Simon, Kathleen Bennett, 

John Feely. (Ireland) 

123 Changes in Prevalence of and Prescribing 

for Ischaemic Heart Disease in Ireland 1990- 

2002 [201] 

Kathleen Bennett, Howard Johnson, Pat Dack, 

John Feely. (Ireland) 

124 Persistence with Different Formulations of 

the Antihypertensive Drug Nifedipine [202] 

Nancy S Breekveldt-Postma, Ron MC Herings. 

(Netherlands) 

125 Assessing the Prevalence and Treatment of 

Coexisting Hypertension and 

Hypercholesterolaemia: A Comparison of 

Two Sampling Methods [203] 

Bryan Williams, Koo Wilson, Loretto Lacey, 

Steve Lister, Nick Marchant, Charles Phillips. 


126 Treatment of High-Risk Hypertensive 

Patients in the United Kingdom: 1997 to 

2001 [204] 

Thomas M MacDonald, Steve V Morant, 

Christine L Baker, Essy Mozaffari. 


127 Use of Platelet Aggregation Inhibitors after 

Ischemic Vascular Events in the 

Netherlands [205] 

Wim G Goettsch, Marco JD Tangelder, Ron 

MC Herings. (Netherlands) 

128 Use of Antihypertensive Drugs and Control 

of Hypertension in Oslo. The Oslo Health 

Study 2000-2001 [206] 

Serena Tonstad, Kari Furu, Elin Olaug 

Rosvold, Svetlana Skurtveit. (Norway) 

129 Can Tight Blood Pressure Control towards 

Ideal Levels Be Cost-Effective? [207] 

Louis Coupal, Steven Grover, Vivian Ho, 

Frédéric Lavoie, Carl Brewer, Hanna Zowall. 

(Canada) 

130 Why Does Consumption of Lipid-Lowering 

Drugs Vary between Regions I Norway? [208] 

Ingeborg H Bartnes, Anne Elise Eggen, Kari 

Furu, Inger Njolstad, Svetlana Skurtveit. 

(Norway) 

131 Real-Life Statin Prescription Patterns in 

South-West France [209] 

Karin Martin, Bernard Bégaud, Abdelilah 

Abouelfath, Philippe Latry, Nicholas Moore. 


132 Impact of an Outpatient Physician 

Education Program on Beta-Blocker Usage 

for Secondary Prevention of Myocardial 

Infarction [210] 

Ilene H Zuckerman, Sheila R Weiss, Diane 

McNally, Barbara Layne, C Daniel Mullins, 

Junling Wang. (United States) 

133 Developing a Method To Identify 

Prescribing Profiles of Antihypertensive 

Drugs in General Practice [211] 

Claudio Voci, Giulia Sangiorgi Cellini, Chiara 

Silvani, Elisabetta Poluzzi, Antonio Vargiu, 

Alberto Vaccheri, Nicola Montanaro, Paolo 

Mosna. (Italy) 

134 The Adherence to Antihypertensive 

Treatments: An Italian Survey by Using 

Prescription Databases [212] 

Elisabetta Poluzzi, Chiara Silvani, Giulia 

Sangiorgi Cellini, Claudio Voci, Petar 

Strahinja, Alberto Vaccheri, Nicola 

Montanaro. (Italy) 

32 




135 Statin Compliance among Newly Treated 

Dyslipidemic Patients in Oman [213] 

Bruno Louis, Kassim A Al Riyamy, Ibrahim S 

Al Zakwani. (Oman) 

136 Insertion/Deletion Polymorphism of the Ace 

Gene and Antihypertensive Response to 

Ace-Inhibitors [214] 

Hedi Schelleman, Olaf H Klungel, Cornelia M 

van Duijn, Jacqueline CM Witteman, Albert 

Hofman, Anthonius de Boer, Bruno HCh 

Stricker. (Netherlands) 

137 Availability of Pharmacogenomics-Based 

Prescribing Information in Drug Package 

Inserts for Currently Approved Drugs [215] 

Issam Zineh, Tobias Gerhard, Christina L 

Aquilante, Amber L Beitelshees, B Nhi 

Beasley, Abraham G Hartzema. (United States) 

138 Interactions between Genetic 

Polymorphisms and Antihypertensive Drugs 

in the Treatment of Hypertension [216] 

Karin JA Lievers, Anthonius de Boer, Bruno 

HCh Stricker, Diane MA de Wijer, Abraham A 

Kroon, Peter W de Leeuw, Cornelia M van 

Duijn, Monique WM Verschuren, Olaf H 

Klungel. (Netherlands) 

139 Defined Daily Dose (DDD) Changes Are 

Associated with Drug Metabolism through 

CYP450 [217] 

Pieter Stolk, Eibert R Heerdink, John 

Urquhart, Hubert GM Leufkens. (Netherlands) 

140 Worldwide Differences in Spontaneous 

Adverse Event Reporting Rates [218] 

Jasmanda H Wu, Wanju S Dai, Paul R 

Lagarenne, Rhonda L Bohn. (United States) 

141 Comparison of Different Methods for Signal 

Detection in the Drug-Safety Database of a 

Pharmaceutical Company [219] 

Markus Follmann, Alexander Michel, 

Christina Geyer. (Germany) 

142 Adverse Drug Reactions and Other Drug 

Related Problems as a Cause of Hospital 

Admission: A Retrospective Study [220] 

Ilma Bertulyte, Jolanta Gulbinovic. (Lithuania) 

143 Safety Profile of Desloratadine as Used in 


Prescription-Event Monitoring Study [221] 

Deborah Layton, Lynda V Wilton, Saad AW 

Shakir. (United Kingdom) 

144 Safety Profile of Levocetirizine as Used in 



Deborah Layton, Lynda V Wilton, Saad AW 


145 Analysis of Design Quality and Potencial 

Bias in Reports Acceptence of Trials on 

Antihypertensive Therapy Presented at the 

12 and 13-Th Meetings of the European 

Society of Hypertension [223] 

Maksim N Mily, Sergey A Golubev. (Sweden) 

146 Predictors of Completed Academic Detailing 

Encounters with Primary Care Physicians 

[224] 

Jennifer M Polinski, M Alan Brookhart, Jerry 

Avorn, Michele Burgener, Danielle Cabral, 

Andrea Licari, Daniel H Solomon. (United States) 

147 The Impact of Prescription Audit on 

Prescribing Skills of Medical Students [225] 

Ahmet Akici, M Zafer Gören, Cenk Aypak, 

Berna Terzioglu, Sule Oktay. (Turkey) 

148 Adverse Event Reporting in Paediatrics [226] 

Mireya R Schmickler. (Germany) 

149 The Importance of the Drug Information 

Center as an Instrument of 

Pharmacovigilance [227] 

Emilia V Silva, Janeth OS Naves, Lia LC 

Castro, Camila Zakir, Carlos CF Vidotti, 

Mariana HM Cunha, Hoefler Rogerio. (Brazil) 

150 Quality Management in Pharmacovigilance: 

Effects on Quality of Reports [228] 

Bina Kramhoft Schack. (Denmark) 

151 Identification of Ophthalmic Adverse Events 

with Particular Reference to Special 

Populations: Can We Learn from Our 

Experience? [229] 

Rhonda L Bohn, Wanju S Dai. (United States) 

152 Day of Hospitalization and Inpatient HIV 

Medication Errors [230] 

C Jessica Dine, Russell Localio, Mark Cary, 

Janet Hines, Amelia Graziani, Robert Gross. 


153 Clinical Trials Are Not Reported Satisfactory 

to the Authorites [231] 

Steinar Madsen, Bente Fjeld, Linda Sandaker, 

Harald Lislevand, Aasmund Reikvam. 

(Norway) 

154 Pharmacovigilance – National Reporting 

System of Monitoring Adverse Reactions of 

Medicinal Products, Via E-Mail, in Brazil 

[232] 

Elenice Lacerda, Murilo F Dias, Nair R Souza, 

Patricia M Figueiredo, Juliana B Barra. (Brazil) 

155 Serious Side-Effects of Bupropion. Who Is at 

Risk among 524 000 Exposed Patients? [233] 

Marie-Noelle Beyens, Silvy Laporte, Michel 

Ollagnier. (France) 

156 Agranulocytosis and Calcium Dobesilate: 

Signal or Not Signal? [234] 

Karin Martin, Bernard Bégaud. 


157 Adverse Drug Reaction Profiles for 

Fluoxetine, Paroxetine and Amitriptyline 

Using Data Recorded by General 

Practitioners in the United Kingdom (UK) 

[235] 

Sarah Davis, Stephan Rietbrock, Carlos 

Martinez. (United Kingdom) 

158 Agreement of Expert Judgment in 

Assessment of Causality of Adverse Drug 

Reactions [236] 

Yannick Arimone, Bernard Begaud, Ghada 

Miremont-Salame, Françoise Haramburu, 

Annie Fourrier-Reglat. (France) 

159 Reports of Cardiovascular Events for 

Sibutramine as Used in General Practice in 

England: Results of a Prescription-Event 

Monitoring Study [237] 

Hilary M Pearce, Lynda V Wilton, Saad AW 


160 Gefitinib-Induced Interstitial Pneumonia in 

Japan. – Problems in the Approval Process, 

Pharmacovigilance and Regulatory 

Decision-Making [238] 

Harue Tada, Naomi Yokoyama, Masatsugu 

Nakagawa, Shigeyuki Matsui, Satoshi 

Teramukai, Masanori Fukushima. (Japan) 

161 Adverse Drug Reactions in an Intensive 

Care Unit [239] 

Luis E Salazar Domínguez, Juan de Dios 

Hernández Beguiristaín, Jorge R Pérez Cruz, 

Jorge Diaz Mayo. (Cuba) 

162 Use of Anti-Inflammatory Therapy and 

Asthma Mortality in Portugal from 1991- 

2001 [240] 

Magda N Melo, Zilda Mendes, Paula Martins, 

Samy Suissa. (Portugal) 

163 Pharmacovigilance and Reporting 

Therapeutic Ineffectiveness as an Adverse 

Drug Reaction in Brazil [241] 

Nair R Souza, Murilo F Dias, Elenice Lacerda, 

Patricia M Figueiredo, Juliana B Barra, Esther 

S Silva, Dayana A Silva. (Brazil) 

164 Stavudine Usage and the Incidence of 

Peripheral Neuropathy in HIV/AIDS 

Patients [242] 

Gordana J Dragovic, Djordje Lj Jevtovic. 

(Yugoslavia) 

END - Session A 


✒

POSTER SESSION B • TUESDAY, 24 AUGUST, 2004 

1 A Randomised, Controlled Trial of 

Antipsychotic Drug Withdrawal in 

Dementia [296] 

Sabine Ruths, Jorund Straand, Harald A 

Nygaard. (Norway) 

2 Impact of the New Guidelines from the 

French Medicine Agency (Afssaps) on Low 

Molecular Weight Heparin Use in a French 

University Hospital [297] 

Sophie Leclerc, Haleh Bagheri, Kamran Samii, 

Jean-Louis Montastruc, Maryse Lapeyre- 

Mestre. (France) 

3 Targeted Academic Detailing To Reduce 

Suboptimal Antimicrobial Use in a Teaching 

Hospital [298] 

Charles A Morris, Fischer Michael, Jerry 

Avorn. (United States) 

4 Impact of a Two Phase Intervention on 

Antimicrobial Prescribing Behavior [299] 

Peter GM Mol, Prashant V NannanPanday, 

Jaap E Wieringa, Rijk OB Gans, John E 

Degener, Marian Laseur, Flora M Haaijer- 

Ruskamp. (Netherlands) 

5 Impact of Generic Substitution on 

Ambulatory Drug Costs in Finland [300] 

Tinna J Voipio, Pirkko K Paakkari, Erkki S 

Palva, Esko J Nuotto. (Finland) 

6 Mortality Increase after Coprescribing 

Cisapride and Contraindicated Drugs [301] 

Nam-Kyong Choi, Yooni Kim, Seung-Mi Lee, 

Hwa-Jung Kim, Byung-Joo Park. (Korea) 

7 Challenges and Lessons in 

Pharmacoepidemiology: Analyzing 

Longitudinal Data [302] 

Caro Badcock, Lisa G Pont, Stephen J Kerr, 

Judith M Mackson, John Mandryk, Sonia 

Wutzke, Lynn Weekes. (Australia) 

8 Dosage of Anti-Hypertensive Drugs and 

Stroke Incidence among Hypertensives [303] 

Fausto Marchetta, Mirko Di Martino, Giorgia 

Valpiani, Rossella Miglio, Leona Bassein, 

Alessandra Sturani, Ezio Degli Esposti. (Italy) 

9 Prescription of Homeopathics and Herbal 

Medicines before and during Pregnancy [304] 

Veronika Egen-Lappe, Joerg Hasford, Martina 

Koethemann. (Germany) 

10 Persistence with Antihypertensive Therapy 

in Newly Diagnosed Patients - A Population- 

Based Study [305] 

Chantal Bourgault, Martin Sénécal, Marc 

Brisson, Michael Marentette, Grégoire Jean- 

Pierre. (Canada) 

11 Factors Associated with the Initiation and 

Discontinuation of Secondary Stroke 

Prevention Agents in US Nursing Homes [306] 

Carmel M Hughes, Kate L Lapane. 


12 Is Hospitalisation a Determinant of 

Initiation and Long-Term Use of 

Benzodiazepines? [307] 

Rutger Stuffken, Kris LL Movig, 

Toine CG Egberts. (Netherlands) 

13 Drug Utilization Review (DUR) for the 

Treatment of Asthma [308] 

Joëlle Mimeault, Diane Blais, Members of the 

Conseil du médicament. (Canada) 

14 The Association between Area-Based 

Deprivation and Prescribing Patterns in 

Ireland [309] 

Cara Usher, Kathleen Bennett, John Feely. 

(Ireland) 

15 Does the Organization of Maternity Wards 

Affect Postnatal Drug Use? [310] 

Hedvig Nordeng, Britt-Ingjerd Nesheim, Anne 

Eskild, Ivar Aursnes. (Norway) 

16 Patient Persistency with Topical Ocular 

Hypotensive Therapy [311] 

Beth L Nordstrom, David S Friedman, Essy 

Mozaffari, Reinee E Sheffield, Harry A 

Quigley, Alexander M Walker. (United States) 

17 Quinolone Utilisation in Children and 

Adolescents [312] 

Ahmet Akici, Corinne S de Vries. (Turkey) 

18 Use of Herbal Products during Pregnancy 

[313] 

Carol Louik, Margaret A Honein, Martha M 

Werler, Allen A Mitchell. (United States) 

19 Methodological Issues in Determining Daily 

Hormonal Contraceptive Exposure on the 

General Practice Research Database [314] 

Julia M Snowball, Richard DT Farmer. 


20 Does the Early Adopter of Drugs Exist? A 

Population Based Study of General 

Practitioners’ Prescribing of New Drugs [315] 

Torben Dybdahl, Morten Andersen, Jens 

Sondergaard, Jakob Kragstrup, Ivar Sonbo 

Kristiansen. (Denmark) 

21 Therapeutic Traditions and Compliance 

with Local Therapeutic Guidelines on Lipid 

Lowering Drugs - A Multilevel Analysis in 

the Skaraborg Primary Healthcare Database 

(SPHD) [316] 

Per Hjerpe, Juan Merlo, Ulf Lindblad, Sven 

Fornwall. (Sweden) 

22 Analysing Drug Overuse in a Prescription 

Database: Estimation Method Matters [317] 

Morten Andersen, Jens Soendergaard. 

(Denmark) 

23 Drug Interactions in Primary Care: Impact 

of a New Algorithm on Risk Determination 

[318] 

Verena Bergk, Christiane Gasse, Dietrich 

Rothenbacher, Michael Loew, Hermann 

Brenner, Walter E Haefeli. (Germany) 

24 Pattern of Use of NSAIDs in the Italian 

General Population: A Questionnaire-Based 

Study [319] 

Domenico Motola, Elisabetta Poluzzi, Chiara 

Silvani, Claudio Voci, Fabrizio De Ponti, 

Alberto Vaccheri, Nicola Montanaro. (Italy) 

25 Impact of Potentially Inappropriate Drug 

Use on Mortality among Nursing Home 

Residents [320] 

Brian J Quilliam, Muhammed S Alsultan, E 

Paul Larrat, Kate L Lapane. (United States) 

26 Non-Adherence to Evidence-Based 

Guidelines in the Initial Treatment of 

Hypertension [321] 

Michael A Fischer, Raisa Levin, Jerry Avorn. 


27 Doctor-Shopping for Buprenorphine in a 

French Region: Method for Assemement 

and Trends from 2000 to 2002 [322] 

Vincent Pradel, Xavier Thirion, Christine 

Coudert, Alain Masut, Joëlle Micallef. (France) 

28 Socio-Demographic Risk Factors for 

Polymedication in a French Community- 

Dwelling Elderly Population: Results from 

the Three-City Study [323] 

Nathalie Lechevallier-Michel, Annie Fourrier- 

Reglat, Jean-Francois Dartigues, Annick 

Alperovitch. (France) 

29 Socio-Economic Inequalities in the Use of 

Antidepressants? [324] 

Dorte Gilså Hansen, Jens Soendergaard, 

Werner Vach, Lars F Gram, Jens-Ulrik 

Rosholm, Preben B Mortensen, Jakob 

Kragstrup. (Denmark) 

30 Trends in Antibiotic Consumption in 

Ambulatory Care in Europe [325] 

Monique M Elseviers, Robert H Vander 

Stichele, Matus Ferech, Herman Goossens, 

ESAC Management Team. (Belgium) 

31 Appropriateness of Clopidogrel Prescribing 

in a Primary Care Setting [326] 

Janice Watt, Richard Lowrie, Keith Beard, 

Anne Lee. (United Kingdom) 

32 Antidiabetic Prescribing Patterns in 

Portuguese Type 2 Diabetics – Collecting 

Valuable Information To Estimate Disease 

Prevalence [327] 

Filipa Duarte-Ramos, Jose Cabrita. (Portugal) 

33 Prescription Patterns of Oral Anticoagulants 

and Knowledge of Outpatients about Their 

Treatment: The Impact of an Information 

Campaign in France [328] 

Association Francaise des Centres, Regionaux 

de Pharmacovilance. (France) 

34 A First Year of Generic Substitution; How 

Do Doctors, Patients and Pharmacy Staff 

Act? Experiences from Region Västra 

Götaland, Sweden [329] 

Karolina Andersson, Anders Carlsten, Knut 

Lönnroth, Max Petzold, Christian Sonesson. 

(Sweden) 

35 Antipsychotic Treatment Patterns among 

French Schizophrenic Outpatients: The Epi 

Survey [330] 

Patrick Blin, Jean-Pierre Olié, Philippe 

Cialdella, Alain Gérard, François PetitJean, 

Daniel Sechter, Linda Hanssens, Jérémie 

Westerloppe. (France) 

34 




36 Calcium and Vitamin D Supplement Use in 

Lon-Term Care Residents [331] 

Stephen P Motsko. (United States) 

37 Deliveries of Anxiolytics, Hypnotics and 

Antidepressants to Adolescents in a French 

Region in 2002 [332] 

Julien Mancini, Xavier Thirion, Alain Masut, 

Carine Saillard, Vincent Pradel, Fanny 

Romain, Christine Coudert, Joëlle Micallef. 

(France) 

38 Can Local Consensus Process and Peer 

Review Improve Treatment for Chronic 

Cardiovascular Problems? [333] 

Willeke Kasje, Petra Denig, Pieter de Graeff, 

Flora M Haaijer-Ruskamp. (Netherlands) 

39 Social and Behavioral Characteristcs of 

Aspirin Users: Japan Nurses’ Health Study 

[334] 

Kota Katanoda, Yasuhiro Matsumura, 

Hirofumi Takagi, Jung Su Lee, Toshiharu 

Fujita, Kunihiko Hayashi. (Japan) 

40 Drugs Used in Euthanasia and Physician 

Assisted Suicide in Four European 

Countries [335] 

Johan Bilsen, Agnes van der Heide, Freddy 

Mortier, Michael Norup, Eugenio Paci, Gerrit 

van der Wal, Rurik Lofmark, Georg Bosshard, 

and on behalf of the Eureld Consortium. 

(Belgium) 

41 The Impact of an Unrestricted Access Policy 

for Atypical Antipsychotic Medications in 

Newfoundland and Labrador [336] 

Daria J O’Reilly, Patrick S Parfrey. (Canada) 

42 What Is My Indicator Telling Me?: 

Dilemmas in Interpreting Prescribing 

Indicators [337] 

Lisa G Pont, Jacoba P Greving, Heidrun 

Sturm, Flora Haaijer-Ruskamp. (Australia) 

43 Clinical Correlates and Drug Treatments of 

a Nursing Home Population with a Recent 

Stroke and Comorbid Depression [338] 

Brian J Quilliam, Matthew M Lacroix, Kate L 

Lapane. (United States) 

44 Surgery Versus Radiation: Is There a 

Difference in Prostate Cancer-Specific 

Mortality? [339] 

Michael D Taylor. (United States) 

45 The Effect of Hypertension and Hypercholesterolemia 

Screening with Subsequent 

Intervention Letter on the Use of Blood 

Pressure and Lipid Lowering Drugs [340] 

Jarir Atthobari, Taco BM Monster, Paul E de 

Jong, Lolkje TW de Jong van den Berg. 

(Netherlands) 

46 Multivitamin Use among Children Aged 2- 

11 Years [341] 

Judith P Kelly, David W Kaufman, Lynn 

Rosenberg, Allen Mitchell. (United States) 

47 Sleeping Pill Use and Users’ Characteristics: 

Japan Nurses’ Health Study [342] 

Shuku Fujimaki, Toshiharu Fujita, Shosuke 

Suzuki, Hideki Mizunuma, Takeshi Aso, 

Alexander Walker, Kunihiko Hayashi. 


48 Contraindicated Drug Prescriptions to 

Children [343] 

Lamiae Bensouda, Annie Pierre Jonville-Bera, 

Nathalie Sarraf, Francoise Doisy, Elisabeth 

Autret-Leca, Jacques Pivette. (France) 

49 Potentially Inappropriate Medication Use by 

Patients 70 Years and Older [344] 

Marie-Laure Laroche, Yves Nouaille, Monique 

Amaniou, Jean-Pierre Charmes, Louis Merle. 

(France) 

50 Detection and Treatment of Depression in 

General Practice [345] 

Ahmad Al-windi. (Sweden) 

51 Evidence Based Treatment Training 

Intervention for Reducing Medication Errors 

in Primary Health Centres [346] 

Erna Kristin, Iwan Dwiprahasto, Jarir At 

Thobari. (Indonesia) 

52 Impact of the Withdrawal of Cerivastatin 

on the Prescribing Patterns of the Other 

Statins [347] 

Therese M Rafferty, Briegeen G Girvin, 

Michael R Stevenson, Dennis G Johnston. 


53 The Nordic Method for Quality 

Improvement in General Practice: A 

Randomised Controlled Study [348] 

Jens Sondergaard, Dorte Gilså Hansen, Peter 

Aarslev, Henrik Stovring, Anders Peter 

Munck. (Denmark) 

54 Utilization of Psychotropic Drugs in Banja 

Luka Region (North-West Bosnia): 8-year 

Follow-Up [349] 

Lana Nezic, Ranko Skrbic, Svjetlana 

Stoisavljevic Satara, Natasa Stojakovic, 

Milenka Vucen. (Bosnia and Herzegowina) 

55 Misuse of Clonazepam in France: 

Prescription Database Analysis [350] 

Elisabeth Frauger, Xavier Thirion, Charles 

Chanu, François Natali, Chantal Gatignol, 

Carine Saillard, Vincent Pradel, Patrick 

Reggio, Joëlle Micallef. (France) 

56 Simple Economic Model of Hiv/Aids 

Prevention and Treatment in Private Sector 

Settings for Developing Countries [351] 

Douglas E Ball, Klara Tisocki. (Kuwait) 

57 Patterns of Risperidone Prescriptions: A 

Utilization Study in Soutwest France [352] 

Karin Martin, Bernard Bégaud, Hélène 

Verdoux, Nathalie Lechevallier, Philippe Latry, 

Nicholas Moore. (France, Metropolitan) 

58 “Ten Wise Tips about Medications” - A 

Computerised Tool for Self Directed 

Monitoring of Adherence of Public Health 

Issued Guidelines in the Health Care System 

in Stockholm [353] 

Per Gæransson, Sten Ronge, Œke Karlsson, 

Ann-Sofie Mangs, Bjœrn Wettermark, Ulf 

Bergman, Lars L Gustafsson. (Sweden) 

59 Antibiotics: Evolution of Prescription’s 

Behaviour in France [354] 

Julie Biga, Florence Taboulet, Maryse Lapeyre- 

Mestre, Robert Bourrel, Vincent Sciortino, 

Alain Grand, Jean-Louis Montastruc. (France) 

60 Evaluation of Drug Formulary System 

Suitability for Improving Pharmaceuticals 

Supply and Utilization in Hospital Setting 

in Belarus [355] 

Maksim N Mily, Irina M Samsonova, Vladimir 

Y Lugovoy. (Sweden) 

61 Extended and Targeted Drug Information at 

Pharmacies: Attitudes to the Concept and 

Barriers To Impact [356] 

Jens Sondergaard, Annette Foged, Morten 

Andersen. (Denmark) 

62 Improved Adherence to Guidelines by 

Outpatient Prescription Feedback to 

Hospital Based Specialists – A Controlled 

Intervention Study [357] 

Bjorn Wettermark, Kjell Haglund, Lars L 

Gustafsson, Peter Persson, Ulf Bergman. 

(Sweden) 

63 Do Physicians Agree with Generic 

Substitution? [358] 

Karolina Andersson, Tove Jörgensen, Anders 

Carlsten. (Sweden) 

64 Regional and Social Variation in Iron 

Prescribing to Pregnant Women [359] 

Barbara Rebhan, Christine Strunz-Lehner, 

Veronika Egen-Lappe, Joerg Hasford, Katrin 

Janhsen, Gerd Glaeske. (Germany) 

65 Potential Drugs Interactions Deriving from 

the Use of Over-the-Counter (OTC) 

Medicines [360] 

Maria Jesus Aragon-Martinez, Maria Luisa 

Martin-Calvo, Ramona Mateos-Campos. (Spain) 

66 Evaluation of Drug Misuse in 

Gastrointestinal Bleedings Collected in the 

University Hospital of Dijon (France) [361] 

Catherine Sgro, Francois Clinard, Cyril Hatem, 

Salwa Layka, Anne Disson-Dautriche, Olivier 

Coatmeur, Patrick Hillon. (France) 

67 Characteristics of Physicians Who 

Prescribed and Did Not Prescribe 

LOTRONEX® (ALOSETRON HCL) after Its 

Reintroduction [362] 

Gregg S Wilkinson, Alexander M Walker, 

Heather Norman, Suzanne F Cook. 


68 The Impact of Region and Social Status on 

Drug Prescribing during Pregnancy [363] 

Christine Strunz-Lehner, Veronika Egen- 

Lappe, Joerg Hasford, Katrin Janhsen, Gerd 

Glaeske. (Germany) 

69 The Utilization Pattern of Carbamazepine of 

Three Medical Centers in Taiwan [364] 

Yao-Teh You, Chiung-Fang Tai, Churn-Shiouh 

Gau. (Taiwan) 

70 Prescribing Patterns of Common Antibiotics 

Used in a Neonatal Intensive Care Unit 

(NICU) [365] 

Ching-Lan Cheng, Yea-Huei Kao Yang, Shu- 

Hua Tai, Yuh-Jyh Lin, Chyi-Her Lin. (Taiwan) 

71 Content of the Medicine Cupboards of a 

Sample of South African Households [366] 

Ilse Truter, Suzette Blignault. (South Africa) 


✒


72 Antidepressant Dispensings for Post-Stroke 

Veterans [367] 

L Douglas Ried, Michael J Tueth, Diane 

McMullen. (United States) 

73 Regulatory Action and Trends in 

Prescribing of Epoetins and Spontaneous 

Suspected ADR Reports of Pure Red Cell 

Aplasia (PRCA) in the United Kingdom 

(UK) [368] 

Emma L Heeley, William N Richardson. 


74 The Potential Drug-Drug Interactions in an 

Ambulatory Prescription Data in Taiwan [369] 

Mei-shu Lin, Nen-Chung Chang, Yea-huei Kao 

Yang, Yen-Hui Chen. (Taiwan) 

75 Increased Prescribing of Anti-Osteoporotic 

Therapy Following Exposure to Inhaled 

Steroids [370] 

David Williams, Kathleen Bennett, John Feely. 


76 Subdosing of Antibiotics in Children with 

Cardiovascular Disease [371] 

Milica Bajcetic, Nevena Divac, Slavko 

Simeunovic, Ranka Samardzic. (Yugoslavia) 

77 Deaths In Young Women Using Flutamide 

in Brazil [372] 

Patricia M de Figueiredo, Esther S da Silva, 

Murilo F Dias, Nair R de Souza, Elenice 

Lacerda, Danila AV Barca. (Brazil) 

78 Monitoring the Effects of New Evidence on 

Menopausal Hormone Therapy Prescription 

Patterns [373] 

Bernhilde Deitermann, Katrin Janhsen, Petra 

Kolip, Gerd Glaeske. (Germany) 

79 Drug Use Evaluation of Colony Stimulating 

Factors in Sultan Qaboos University 

Hospital in Oman [374] 

Badria A Al-Zadjali, Mansour Al-Moundhri, 

Yasser A Wali, Kassim A Al-Riyami. (Oman) 

80 Appropriate Prescribing for Persons at High 

Risk of GI Complications: Current Findings 

from General Practice [375] 

Colleen J Metge, Malcolm Doupe, Alan Katz, 

Brent Kvern, Lori-Jean Manness, Glen 

Thomson, Marina Yogendran. (Canada) 

81 Quantitative Analysis of the Reimbursement 

Procedure in Belgium [376] 

Alain G Dupont, Philippe B Van Wilder, Jean 

Paul Degaute, Hugo Robays, Francis Arickx, 

Gert A Verpooten. (Belgium) 

82 Early Discontinuation of Antidepressants in 

General Practice: Association with Patient 

and Prescriber Characteristics [377] 

Dorte Gilså Hansen, Werner Vach, Jens-Ulrik 

Rosholm, Jens Soendergaard, Lars F Gram, 

Jakob Kragstrup. (Denmark) 

83 A Study of Incidence of Pancytopenia in 

Patients Taking Leflunomide Alone or with 

Methotrexate [378] 

John McEwen, Richard L Hill, Patrick M 

Purcell, Lisa J Calcino, Cathy G Riley. 

(Australia) 

84 Anti-Hypertensive Drug Use Amongst Men 

with LUTS/BPH [379] 

Annie Hutchison, Richard DT Farmer. 


85 Analysis of Antipyretic Prescriptions to 

Children Aged 12 Years or under in French 

Office Based Medical Practice [380] 

Annie Pierre Jonville-Bera, Bruno Giraudeau, 

Jean Deligne, Claudine Blum-Boisgard, 

Elisabeth Autret-Leca. (France) 

86 Challenges in Measuring Improved 

Appropriateness of Oral Hypoglycaemic and 

Other Drug Use in Type 2 Diabetes in 

Primary Care [381] 

Judith M Mackson, Lynne McMartin, Sheena 

O’Riordan, Margaret Fitzgerald, Kylie Easton, 

Lynn M Weekes. (Australia) 

87 Drug Utilization by Retired People: Results 

from Postal and Domiciliary Surveys in Belo 

Horizonte / MG, Brazil [382] 

Andreia Q Ribeiro, Francisco A Acurcio, Suely 

Rozenfeld, Carlos H Klein, Cristiano S Moura, 

Celia Andrade. (Brazil) 

88 Clinical Guidelines and Feedback to GPs 

and Hospital Doctors Improves Prescription 

Habits [383] 

Kirsten Schaefer, Lars Onsberg Henriksen. 

(Denmark) 

89 How Should We Assess the Clinical 

Relevance of Guidelines in Primary Health 

Care? [384] 

Liselotte LvF von Ferber, Christian CvF von 

Ferber. (Germany) 

90 Drug Utilization by Children and 

Adolescents with Mental Retardation: A 

Unique Population Study [385] 

Hilde Tobi, Karin A Netjes, Erik Mulder, Tom 

Scheers. (Netherlands) 

91 Doping in Sports: Knowledge of Prohibited 

Substances by Community Pharmacists [386] 

Genevieve Durrieu, Marie Noyer, Jean-Louis 

Montastruc. (France) 

92 Evolution of Antidepressives Comsumption 

in the Valenciana Community in the 2000- 

2002 Period [387] 

Encarna Cardo, Laura Monzon, Fernando 

Fernandez-Llimos, Maria Jose Faus, Amalia 

Ubeda. (Spain) 

93 Monitoring Drug Prescription for Attention- 

Deficit / Hyperactivity Disorder (ADHD) 

[388] 

Katrin Janhsen, Gerd Glaeske, Elke 

Scharnetzky, Christel Schicktanz, Andrea 

Ludolph, Fegert Joerg. (Germany) 

94 Study of the Prescriptions for Obesity at 

Drugstores in Distrito Federal, Brazil [389] 

Rogerio Hoefler, Claudio Valdivino e Silva, 

Valdete A Melo, Ana Paula P Lima, Marcus 

Tolentino, Emilia V Silva, Carlos CF Vidotti, 

Mariana HM Cunha, Amanda A Ferreira. (Brazil) 

95 Consumption of Lipid-Lowering Agents in 

Hungary (1993-2003); Impact of Individual 

Economic Burden [390] 

Gyongyver Soos, Edit Kosik, Gabor Nagy. 

(Hungary) 

96 Self Medication with Antibiotics in Czech 

Republic [391] 

Retnosari Andrajati, Jiri Vlcek, Flora M 

Haaijer-Ruskamp. (Czech Republic) 

97 Drug Consumption during Late Pregnancy 

and in Post-Partum Period: A Comparative 

Study between Lactating and Non-Lactating 

Women [392] 

Aurelie Olanor, Isabelle Lacroix, Michel 

Rolland, Jean-Louis Montastruc, Christine 

Damase-Michel. (France) 

98 Drug Utilization Profile among Brazilian 

Elderly People [393] 

Carlos H Klein, Francisco A Acurcio, Suely 

Rozenfeld, Andreia Q Ribeiro, Cristiano S 

Moura, Celia Andrade. (Brazil) 

99 Use of Antilipemic Drugs in National 

Healthcare Group (NHG), Singapore [394] 

Boon Peng Lim, Benjamin KC Ong. (Singapore) 

100 Prevalence, Predictors and Outcomes of the 

Inappropriate Drug Prescribing in Frail 

Community-Living Elderly: Eastern 

European Country Study [395] 

Daniela Fialova, Eva Topinkova, Jiri Vlcek, 

Roberto Bernabei. (Czech Republic) 

101 Medicines Selection by Physicians and 

Patients in Armenia [396] 

Irina Kazaryan, Margarita Melikyan, Anahit 

Amirkhanyan, Naira Hovsepyan. (Armenia) 

102 Tramadol Prescribing Pattern among Italian 

General Practitioners: A Population-Based 

Study [397] 

Gianluca Trifirò, Emiliano Sessa, Giampiero 

Mazzaglia, Pierangelo Lora Aprile, Gino 

Cancian, Ovidio Brignoli, Claudio Cricelli, 

Achille P Caputi. (Italy) 

103 Drug Use and Information Sources in Rural 

Areas in Lithuania /Results Based on 

Investigations in Alytus Region/ [398] 

Jurga Saskovaite, Romaldas Maciulaitis. 

(Lithuania) 

104 Study on Utilization of Drugs for Peptic 

Ulcer [399] 

Shengxin Chen, Lin Ma, Xiaofang Chen. 

(China) 

105 Determinants of Medicine Use in a Swedish 

Primary Health Care Practice Population 

[400] 

Ahmad Al-Windi. (Sweden) 

106 Quantitative Assessment of the Prescribing 

in the Teaching Hospital Using the 

Methodology Drug Utilisation DU90% in 

Two Consequent Years [401] 

Rachel Pipalova, Jiri Vlcek, Karel Macek. 

(Czech Republic) 

107 Use of Medicines by University Students [402] 

Ramona Mateos-Campos. (Spain) 

36 




108 A Patient Exposure Estimation Database [403] 

Joanne J Hunold, Mary Y Park, Daniel Fife. 


109 Qualitative Evaluation of an Outcomes 

Guarantee Project for Lipid Lowering 

Drugs [404] 

Stephen R Chapman, Maria Allinson. 


110 Methodological Issues in Evaluation of 

Interventions To Improve Hospital 

Antibiotic Prescribing: Measuring What and 

How? [405] 

Faranak Ansari, Dilip Nathwani, Craig 

Ramsay, Peter G Davey. (United Kingdom) 

111 The Risk of Myocardial Infarction and Case 

Fatality in Users of Antidiabetics [406] 

Mette Lena Olsen, Taco BM Monster, Soren P 

Johnsen, Joseph K McLaughlin, Henrik Toft 

Sorensen, Hans H Lervang, Jorgen Rungby. 

(Denmark) 

112 Diabetes Increases the Risk of Drug-Induced 

Torsades De Pointes: Analysis of Data from 

the French Pharmacovigilance Database [407] 

Atul Pathak, Jean-Francois Tournamille, Jean- 

Michel Senard, Jean-Louis Montastruc, 


113 Declining Blood-Pressure in Monica 

Populations - Is the Bell Curve Shifted Left 

or Flattened at the High End? Preliminary 

Analysis [408] 

Hugh Tunstall-Pedoe, John Connaghan, 

Richard A’Brook. (United Kingdom) 

114 Risk of Adverse Birth Outcome for Pregnant 

Users of Pivmecillinam - A Population 

Based Cohort Study [409] 

Mette Vinther Skriver, Mette Norgaard, Lars 

Pedersen, Henrik C Schonheyder, Henrik Toft 

Sorensen. (Denmark) 

115 Intrauterine Exposure to Folic Acid 

Antagonists and the Risk on Folic Acid 

Sensitive Congenital Anomalies [410] 

Willemijn M Meijer, Hermien EK de Walle, 

Wilhelmina S Kerstjens-Frederikse, Lolkje TW 

de Jong-van den Berg. (Netherlands) 

116 An Evaluation of Norfloxacin Use during 

Pregnancy [411] 

Susan A Galea, Ann R Sweet, Kristine E 

Shields, Lynette E Etzel, Robert G Sharrar, 

Bengt-Erik Wiholm. (United States) 

117 Pregnancy Incidence among Women with 

Inflammatory Skin Disorders [412] 

Lee Lanza, Elena Rivero, Carlos Fernandez, 

William A West, John D Seeger. (United States) 

118 Maternal Use of Loratadine during 

Pregnancy and Risk of Hypospadia in 

Offspring: A Danish Nested Case-Control 

Design [413] 

Lars Pedersen, Mette V Skriver, Henrik T 

Sorensen. (Denmark) 

119 Estimation of Variation in Congenital 

Anomaly Rate with Gestational Age [414] 

Jim M Slattery. (United Kingdom) 

120 The Management and Outcomes of Patients 

Prescribed Rosiglitazone in Primary Care in 

England [415] 

Lynda V Wilton, Pipasha Biswas, Beate 

Barrera, Saad AW Shakir. (United Kingdom) 

121 Does an Automated Thyroid Register 

Improve the Chronic Management of 

Hypothyroid Patients?: An Observational 

Study [416] 

Robert WV Flynn, Thomas M MacDonald, 

Andrew D Morris, Roland T Jung, Graham P 

Leese. (United Kingdom) 

122 Patients’ Opinions of Their Diabetes Control 

Is Associated with the Frequency of Self- 

Monitoring of Blood Glucose [417] 

Michiel J Storimans, Olaf H Klungel, Herre 

Talsma, Annemieke Floor-Schreudering, 

Cornelis J de Blaey. (Netherlands) 

123 Assessing the Association between Impaired 

Fasting Glucose, Diabetes, and Erectile 

Dysfunction: The Cansed Study [418] 

Steven Grover, Mohammed Kaouache, Ilka 

Lowensteyn, Sylvie Marchand, Louis Coupal, 

Isabelle Defoy, Emidio DeCarolis. (Canada) 

124 Glycemic Effects of Hormone Replacement 

Therapy: Results of German National Health 

Surveys from 1984 to 1999 [419] 

Yong Du, Hans-Ulrich W Melchert. (Germany) 

125 Incident Use of Thiazolidinediones Versus 

Metformin in Medicaid Managed Care Plans 

[420] 

Fadia T Shaya, James Y Shin, C D Mullins, 

Shonda Foster, Hugh O Fatodu. (United States) 

126 Ophthalmological Events in Patients Taking 

Risedronate: Follow up Information in a 


Beate Barrera, Lynda V Wilton, Saad AW 


127 The Management and Outcomes of Patients 

Prescribed Pioglitazone in Primary Care in 

England; Interim Results [422] 

Lynda V Wilton, Beate Barrera, Saad AW 


128 Results of a Post Marketing Surveillance 

Study in Japan Using Rh-Gh in Patients 

with Turner Syndrome without Epiphyseal 

Closure [423] 

Yoshie Kojima, Noriko Kobayashi, Noriko 

Nakamura, Kazuhiro Tsuchitani, Atsushi 

Watanabe, Ekaterina Koledova, Shohei Akita. 

(Japan) 

129 Screening Logic To Establish the Incidence 

of Preventable Hypoglycemic Events in 

Acute Care [424] 

Almut G Winterstein, Thomas E Johns, Randy 

C Hatton, Eric I Rosenberg, Ricardo Gonzalez- 

Rothi, Wendy D Smith. (United States) 

130 An Assessment of the Potential for 

Indication Bias in the Management of 

Chronic Health Conditions [425] 

Linda Levesque, Sophie Dell’Aniello, Samy 

Suissa. (Canada) 

131 Incidence and Prevalence of Patients 

Receiving Insulin and Oral Antidiabetics; a 

Danish Register Based Study from 1991- 

2003 [426] 

Reimar W Thomsen, Gunnar L Nielsen, Hans- 

Henrik Lervang, Henrik T Sorensen. 

(Denmark) 

132 The Hepatotoxicity of TZDS Observed in a 

Medical Center in Taiwan [427] 

Ling-Yu Liu, Churn-Shiouh Gau. (Taiwan) 

133 Pilot Project for Education of Patients with 

Type 2 Diabetes by Pharmacists in Bulgaria 

[428] 

Valentina B Petkova, Guenka I Petrova, Anna 

V Peneva. (Bulgaria) 

134 Statins and Cancer Risk: An Analysis of 

Clinical and Epidemiological Data [429] 

Miguel Gil, Claudio R Gimpelewicz, Michele 

Bortolini, Luis A Garcia, John O Logan, Yan 

Jia, Serguei Titaevski, Shepherd Mutyora, 

Christiane Sleboda. (Spain) 

135 A Cohort Study To Monitor the 

Management and Outcomes of Patients 

Prescribed Carvedilol for Cardiac Failure in 

England [430] 

Lynda V Wilton, Beate A Bearra, Vanessa 

Marshall, Saad AW Shakir. (United Kingdom) 

136 Association between Captopril, Other 

Antihypertensive Drugs and Risk of 

Prostate Cancer [431] 

Luis A Garcia Rodriguez, Ana Ruigomez, Saga 

Johansson, Mari-Ann Wallander, Goran Fritz, 

Kurt Svardsudd, Gunnar Ronqvist. (Sweden) 

137 Irbesartan Associated Cholestatic Hepatic 

Change: A Randomized Controlled Clinical 

Trial [432] 

Hwa-Jung Kim, Hyun-Sook Hong, Nam-Kyung 

Choi, Seung-Mi Lee, Yooni Kim, Myung-Mook 

Lee, Byung-Joo Park. (Korea) 

138 Assessing the Occurrence of Adverse Effects 

of Angiotensin-Converting Enzyme (ACE) 

Inhibitors in Patients 65 and Older Using 

the U.S. Food and Drug Administration 

(FDA) Adverse Event Reporting System 

(AERS) Known as Medwatch [433] 

Jennie Y Chou, John R Litaker, James P 

Wilson, Suneet D Gandhi. (United States) 

139 Life-Threatening Ventricular Arrhythmia 

and Sudden Death in Users of Oxybutynin 

and Tolterodine [434] 

Kay Patterson, Iyue Sung, Gerry Faich, John D 

Seeger. (United States) 

140 Responsiveness of the Self-Esteem and 

Relationship Questionnaire in Men with 

Erectile Dysfunction Treated with Sildenafil 

Citrate in a Double-Blind, Placebo- 

Controlled Trial [435] 

Joseph C Cappelleri, Michael P O’Leary, 

Stanley E Althof, Sandeep Duttagupta, Nancy 

Sherman, Arthur R Crowley, Richard Siegel, 

Li-Jung Tseng, Dale B Glasser. (United States) 


✒


141 Kidney Transplantation and Associated 

Immunosuppressive Therapy Impact on 

Patient’s Quality of Life [436] 

Carla Teixeira de Barros, Jose Cabrita, Sabina 

de Geest, Philip Moons. (Portugal) 

142 Evidence Based Review of Luteinizing 

Hormone Releasing Hormone (LHRH) 

Agonists in Metastatic Prostate Cancer [437] 

Michael Iskedjian, Thomas R Einarson, 

Michiel E Hemels, Neill Iscoe, Neil Fleshner, 

Colin Vicente. (Canada) 

143 Lower Urinary Tract Symptoms in an 

Unselected Sample of Men Aged 55-75 Years 

- Association with Drug Use and Creatinine 

Levels [438] 

Christopher KT Farmer, Satish Jayawardene, 

Steven H Sacks, Richard DT Farmer. 


144 Low-Dose Oral Contraceptive Use and 

Users’ Characteristics: Unapproved Use for 

Endometriosis? - Japan Nurses’ Health 

Study - [439] 

Shuku Fujimaki, Tomoko Kodama, Toshiharu 

Fujita, Shosuke Suzuki, Hideki Mizunuma, 

Takeshi Aso, Michael Reich, Alexander 

Walker, Kunihiko Hayashi. (United States) 

145 Medication Use during the First Trimester 

of Pregnancy [440] 

Anick Bérard, Ariane Malouin, Driss Oraichi, 

Lise Gauthier, Annie Pellerin, Brigitte Martin, 

Sonia Boulanger. (Canada) 

146 Adverse Drug Reactions in Pregnant 

Women [441] 

Isabelle Lacroix, Cendrine Cabou, Jean-Louis 

Montastruc, Christine Damase-Michel. 

(France) 

147 Drugs and Breastfeeding: A French 

Collaboration in a Pharmacoepidemiology 

Study [442] 

Raphael Serreau, Christine Boissinot, Olivier 

Sibony, Aurelie Gilbert, Evelyne Jacqz-Aigrain. 

(France) 

148 A 2004 Review of Pregnancy Outcome 

Datasources [443] 

Marianne C Cunnington, John G Weil, Janet 

Cragan. (United Kingdom) 

149 Are Immunosuppressant Drugs a Risk or a 

Protective Factor for Urinary Leakage in 

Renal Transplantation: A Matched-Paired 

Nested Pilot Case-Control Study Using the 

Controlateral Renal Graft [444] 

Cyril Calvet, Catherine Rioc, Grégoire Robert, 

Jean-Marie Ferrière, Pierre Merville, Karin 

Martin. (France, Metropolitan) 

150 A Patient Follow-Up Survey Program for 

LOTRONEX (Alosetron HCL): Assessing 

Compliance with the Risk Management 

Program [445] 

Elizabeth Andrews, Kelly Hollis, David Miller, 

Pat Tennis, Lee Bennett, Vanessa Ameen, 

Susan Gordon, Amy Heath, David McSorely, 

Suzanne Cook. (United States) 

151 The Concept of “Brand Fidelity” Applied to 

Drug Uptakes by Populations: Examples on 

PPIs and H2RAs [446] 

Hani M Tamim, Marc Dorais, Sophie Rochon, 

Frederic Lavoie, Jacques LeLorier. (Canada) 

152 An Epidemiologic Program for the Study of 

the Safety and Utilization of LOTRONEX 

(Alosetron HCL) in the US [447] 

David P Miller, Alexander M Walker, Jerry 

Avorn, Jerry Gurwitz, Suzanne F Cook, 

Andrew Feld, Pat Tennis, Lotronex 

Collaborative Research Group. (United States) 

153 The Risk of Abdominal and Pelvic Surgery 

among Patients with Irritable Bowel 

Syndrome [448] 

J Alexander Cole, Jason Yeaw, Jennifer A 

Cutone, Braden Kuo, David Earnest, Zhiping 

Huang, Evelyn Rodriguez, Alexander M 

Walker. (United States) 

154 Effect of Control of Confounding in the 

Estimation of the Proportional Reporting 

Ratio [449] 

David Sanchez Matienzo, Jordi Castellsague, 

Alejandro Arana. (Spain) 

155 Determinants for Proton Pump Inhibitor 

Use in Patients with Gastroesophageal 

Reflux by Routine Care [450] 

Michael Kulig, Marc Nocon, Daniel Jaspersen, 

Joachim Labenz, Tore Lind, Wolfgang Meyer- 

Sabellek, Manfred Stolte, Peter Malfertheiner, 

Stefan Willich. (Germany) 

156 Utilization of Alosetron (Lotronex®) by the 

Elderly Prior to and Following the Initiation 

of a Risk Management Program [451] 

Rhonda L Bohn, Wolfgang C Winkelmayer, 

Jennifer M Polinski, Suzanne F Cook, Jerry 

Avorn. (United States) 

157 Prevalence and Demographics of IBS 

Respondents: Results from a Large Web- 

Based Survey [452] 

S C Eaton, E B Andrews, K A Hollis, J S 

Hopkins, V Ameen, L R Hamm, A W Mangel, 

R E Williams, S F Cook. (United States) 

158 Symptoms of Diarrhea-Predominant or 

Alternating IBS: An Exploratory Analysis 

[453] 

S C Eaton, A W Mangel, K A Hollis, V 

Ameen, L R Hamm, E B Andrews, 

R E Williams, S F Cook. (United States) 

159 Characterization of IBS and Non-IBS Patients 

Using Mebeverine in Daily Practice [454] 

Wim G Goettsch, Maarten J ten Berg, Ron MC 

Herings. (Netherlands) 

160 Monitoring of Population Risk of NSAIDs- 

Induced Gastropathy [455] 

Petra Fialova, Jiri Vlcek, Pavel Kohout. 

(Czech Republic) 

161 Therapeutic Regimens for Peptic Ulcer 

Disease. A Treatment Cohort Study [456] 

Ana Paula Martins, Patricia Ferreira, Vera 

Gouveia, Antonio de Sousa Guerreiro, Jose 

Cabrita. (Portugal) 

162 Drug-Induced Pancreatitis: About a Series 

of 49 Cases [457] 

Cécile Beden, Claire Guy, Michel Mallaret, 

Hugues Rousset, Michel Ollagnier. (France) 

163 Ursodeoxycholic Acid in Belgium: The 

Prevalence of Allegedly Stable Biliary 

Diseases Is Not Obvious To Determine from 

Consumption Data [458] 

Marc Van de Casteele, André De Swaef, 

Herman Beyers, Frederik Nevens, Gert A 

Verpooten. (Belgium) 

END - Session B 

WEDNESDAY, 25 AUGUST 2004 

POSTER SESSION C 

1 Perception of the Risk of Anti-Inflammatory 

Drugs in Pregnancy by Pregnant Women: A 

Survey among 250 Women in Midi-Pyrenees 

[513] 

Julie Christaud, Isabelle Lacroix, Alain 

Berrebi, Jean-Louis Montastruc, Christine 

Damase-Michel. (France) 

2 The Incidence of Adverse Drug Events in 

Two Large Academic Long-Term Care 

Facilities: Higher Than Expected? [514] 

Jerry H Gurwitz, Terry S Field, James Judge, 

Paula Rochon, Leslie R Harrold, Cynthia 

Cadoret, Monica Lee, Kathleen White, Jane 

LaPrino, Janet Erramuspe-Mainard, Martin 

DeFlorio, Linda Gavendo, Jill Auger, David W 

Bates. (United States) 

3 Disproportionality Analysis (DPA) To 

Explore Patient and Treatment Related 

Factors Associated with Adverse (AEs) [515] 

Nancy A Yuen, June S Almenoff, William 

DuMouchel, Xionghu Yang, Karol K LaCroix. 


4 A Qualitative Exploration of the Underlying 

Causes of Medication-Related Admissions to 

a Teaching Hospital in the United Kingdom 

[516] 

Rachel L Howard, Anthony J Avery, Paul 

Bissell, Paul Howard. (United Kingdom) 

5 Asking Doctors and Pharmacists To Talk 

about Their Involvement in Preventable 

Medication Related Hospital Admissions [517] 

Rachel L Howard, Anthony J Avery, Paul 

Bissell. (United Kingdom) 

6 Indicators for Preventable Drug-Related 

Morbidity: Facilitating Changes in Practice? 

[518] 

Caroline J Morris, Judith A Cantrill, Anthony 

J Avery, Rachel L Howard. (United Kingdom) 

7 The Association between Risk Factors and 

Warfarin Related Adverse Events: A Case- 

Crossover Study [519] 

Benjamin D Ofori, Peter T Donnan, Barclay M 

Goudie, Peter G Davey. (United Kingdom) 

8 The “Travacalm” Episode [520] 

John McEwen, Jennifer J Robinson, Barry R 

Thompson, Patrick M Purcell, Larry F Kelly, 

Adrian S Krauss. (Australia) 

38 



POSTER SESSION C • WEDNESDAY, 25 AUGUST, 2004 

9 Parental Vaccine Safety Concerns: 

Experiences of Physicians [521] 

Gary L Freed, Sarah J Clark, Beth F Hibbs, 

Jeanne M Santoli. (United States) 

10 Using Stated-Preference Methods to Inform 

Pharmaceutical Risk Management [522] 

Elizabeth Andrews, Reed Johnson. 


11 Comparison and Analysis on Inclusion and 

Ratings of Potential Hepatotoxic Drugs 

among Major Drug Compendia in the 

United States [523] 

Jeff J Guo, Patricia Rozek, Kangsan Lammers, 

Oceana Vu. (United States) 

12 Renal Function Evaluation in the Very 

Old [524] 

Marie-Laure Laroche, Yves Nouaille, Jean- 

Pierre Charmes, Louis Merle. (France) 

13 Diabetes Mellitus Associated with 

Medication Use among Patients with 

Bipolar Disorders in a Managed Care 

Medicaid Population [525] 

Jeff J Guo, Paul E Keck, Raymond Jang, Hong 

Li, Dongming Jiang. (United States) 

14 Influence of Variables on the Time to Onset 

of Adverse Drug Reactions [526] 

Joyce J de Langen, Eugène P van Puijenbroek. 

(Netherlands) 

15 Are Anti-Ulcer Drugs Associated with 

Gynaecomastia, Galactorrhoea, Breast Pain 

and Erectile Dysfunction? [527] 

Linda de Graaf, Eugène P van Puijenbroek, 

Kees van Grootheest. (Netherlands) 

16 The Use of the MHRA/CSM Drug Analysis 

Prints [528] 

Ronald D Mann. (United Kingdom) 

17 Increasing the Effectiveness of Dyslipidemia 

Therapy by Showing Patients Their 

Calculated Coronary Risk: The Importance 

of Cardiovascular Age [529] 

Steven Grover, Ilka Lowensteyn, Louis 

Coupal, Mohammed Kaouache, Carl Brewer. 

(Canada) 

18 Hospitalisation of Elderly Patients Caused 

by Adverse Drug Reactions [530] 

Lionel Bertrand, Pascale Olivier, Marie Tubery, 

Dominique Lauque, Jean-Louis Montastruc, 


19 Detecting Preventable Drug Related 

Morbidity in Ambulatory Care: A Systems 

Perspective [531] 

Brian C Sauer, Charles D Hepler. (United States) 

20 Poor Control of High Blood Pressure and Its 

Correlates in Older People: Community- 

Based Study in Scotland and China [532] 

Ruoling Chen, Li Wei, Roger Tavendale, 

Thomas M MacDonald. (United Kingdom) 

21 Intoxication by Medicinal Plants in Abidjan: 

Clinical, Epidemiological and 

Ethnobotanical Aspects [533] 

Mamadou Kamagate, Henri M Die-Kacou, Eric 

Balayssac, Jean-Claude Yavo, Potey T Daubret, 

Kakou A Kakou, Vamy M Gboignon. (France) 

22 Prescribing Behaviors of General 

Practitioners Visiting Elderly Patients at 

Risk of Iatrogenesis [534] 

Bruno Fantino, Nicolas Voirin, Francoise 

Fantino, Laurent Laforest, Neville Dickson, 

Eric Van Ganse. (France) 

23 Long Term Safety Follow-Up for Cancer 

Progression in Patients Who Had 

Participated in a Randomized Clinical Trial 

of a New Surgical Product [535] 

Joanna F Haas, Stephen Lake, PK Tandon, 

Lena Holmdahl. (United States) 

24 Risk Factors for Pregnancy among 

Isotretinoin Users [536] 

Carla M Van Bennekom, Y Kelly Cho, Allen A 

Mitchell. (United States) 

25 Prescription of Metformin and Renal 

Failure: Are the Present Recommendations 

Approrpiate? [537] 

Michel M Lièvre, Laurent Vaur, Nathalie 

Genes, Michel Marre. (France) 

26 Errors in Medication Administration Are 

Not Accurately Reported in Long Term Care 

Facilities [538] 

Julie Vaillancourt, Jocelyne Moisan. (Canada) 

27 Benefit - Risk Quantitation Based on 

Patient-Reported Outcome Data from 

Women with Diarrheal Irritable Bowel 

Syndrome Treated with Alosetron or 

Placebo [539] 

John R Senior, Ted Guo. (United States) 

28 Risk Benefit Modeling: The Use of Stochastic 

Simulation for Safety Evaluations [540] 

Andrew Maguire, Felix M Arellano, Susana 

Perez-Gutthan, Alejandro Arana. (Spain) 

29 Use of Voluntary Adverse Drug Reaction 

Reporting as a “Quality Indicator” [541] 

Ulf Bergman, Erik Eliasson, Birgitta 

Grundmark, Magnus Korsgren, Gunilla 

Sjoelin-Forsberg. (Sweden) 

30 Adverse Drug Reactions in Children: About 

One Year of Adverse Effects Collected by 

French Pharmacovigilance Centers [542] 

Francoise F Bavoux, Thierry M, Chena S, 

Vauzelle C Gardier. (France) 

31 The European Active Surveillance Study on 

Oral Contraceptives (EURAS-OC). Results 

after 50,000 WY of Observation [543] 

Lothar AJ Heinemann, Anita Assmann, Michael 

Lewis, Doerthe Kuehl-Habich. (Germany) 

32 Evaluation of Combined Oestrogen and 

Progestin or Progestin-Only Exposure of 

Women from Poitou-Charentes Area Who 

Presented a Thromboembolic Event: 

Transversal Study Conducting from May 

2003 to November 2003 [544] 

Sylvie Favrelière, Claire Lafay, Marie-Christine 

Pérault. (France) 

33 Cross-Over Cohort Study of Incident VTE in 

Women Exposed to Cyproterone in UK 

Primary Care [545] 

Jane NS Moseley. (United Kingdom) 

34 The Risk of Venous Thromboembolism 

Associated with Cyproterone Acetate in 

Combination with Ethinyloestradiol - An 

Update [546] 

Helen E Seaman, Corinne S de Vries, Richard 

DT Farmer. (United Kingdom) 

35 Modeling Invasive Meningococcal Disease 

and the Impact of Vaccination [547] 

J Jaime Caro, Denis Getsios, Jörgen Möller. 


36 Macrophagic Myofasciitis (MMF): An 

Exploratory Study To Assess Specificity of 

Clinical Patterns and Vaccines Exposure [548] 

Annie Fourrier-Reglat, Romain Gherardi, Patrick 

Cherin, Jacques Ropers, Costagliola Dominique, 

Daniel Levy-bruhl, Philippe Malfait, Nathalie 

Lechevallier, Carmen Kreft-Jais. (France) 

37 Serious Adverse Events Following Smallpox 

Vaccination among U.S. Civilians [549] 

John Iskander, Christine G Casey, Martha 

Roper, Xiao-Jun Wen. (United States) 

38 A Comparison of Coded Case Definition 

Criteria with Narrative Symptom-Text in the 

U.S. Vaccine Adverse Event Reporting 

System [550] 

Katrin S Kohl, Manya Magnus, Robert Ball, 

Robert P Wise, Neal A Halsey, Thomas A 

Farley. (United States) 

39 Inadvertent Rubella Vaccination during 

Pregnancy: Review of Reports to the U.S. 

Vaccine Adverse Event Reporting System 

(VAERS), 1991-2003 [551] 

Angela Calugar, Vitali Pool, Susan Reef, 

Weigong Zhou, Robert T Chen. (United States) 

40 Adverse Events after Inactivated Influenza 

Vaccination in Children under Age 2 Years: 

Analysis of the Vaccine Adverse Event 

Reporting System, 1990-2003 [552] 

Ann W McMahon, John K Iskander, Penina 

Haber, Soju C Chang, E Jane Woo, M Miles 

Braun, Robert Ball. (United States) 

41 Transient Bulging Fontanelle after 

Vaccinations: Reports to the U.S. Vaccine 

Adverse Event Reporting System [553] 

Stephen B Freedman, John Reed, Dale R 

Burwen, Robert P Wise, Amy Weiss, Robert 

Ball. (United States) 

42 Reports of Elective Termination of 

Pregnancy (ETP) in the Vaccine Adverse 

Event Reporting System (VAERS): 1990 – 

2003 [554] 

Soju Chang, Emily Jane Woo, Dale R Burwen, 

Robert P Wise, Robert Ball, M Miles Braun. 


43 Positive Re-Challenge Reports Following 

Hepatitis B Vaccination in Adults, Vaccine 

Adverse Event Reporting System (Vaers), 

USA, 1995-2003 [555] 

Penina Haber, Weigong Zhou, English Bullard, 

the VAERS Team. (United States) 

44 Inadvertent Administration of Measles 

Vaccine in Early Infancy: A Review of 

Safety Data in the U.S. [556] 

Vitali Pool, Michelle Russell. (United States) 


✒


40 

45 Reports of Brachial Neuritis in the Vaccine 

Adverse Event Reporting System (VAERS), 

United States, 1991 - 2003 [557] 

Weigong Zhou, Vitali Pool, Robert T Chen. 


46 Use of a Medication Identification Booklet 

for OTC Drug Reporting in a Case-Control 

Study of Birth Defects [558] 

Martha M Werler, Sonia Hernandez-Dias, 

Carol Louik, Jane E Sheehan, Allen A Mitchell. 


47 Issues around Psychometrics of the 

Portuguese Version for Portugal of the 

ADDQoL [559] 

Filipa Costa, José Pedro Guerreiro, Brenda 

Madureira. (Portugal) 

48 Validation of a Measurement Scale: The 

Example of a French Adverse Drug 

Reactions ‘ Preventability Scale [560] 

Pascale Olivier, Jacques Caron, Françoise 

Haramburu, Jean-Louis Imbs, Annie-Pierre 

Jonville-Bera, Georges Lagier, Catherine Sgro, 

Thierry Vial, Jean-Louis Montastruc, Maryse 

Lapeyre-Mestre. (France) 

49 A Comparison of Interviewer Versus 

Automated Telephone Administration for 

Ascertaining Sensitive Data [561] 

Suzanne L West, Robert Agans, William 

Kalsbeek, Michael Steinbuch. (United States) 

50 Cluster Analysis of the I-PSS as a Measure 

of Change Following Treatment for 

LUTS/BPH [562] 

Annie Hutchison, Richard DT Farmer. 


51 Causality Assessment of Events Reported 

within an Observationnal Study [563] 

Francoise Haramburu, Ghada M Miremont- 

Salame, Abdelilah Abouelfath, Anne Laribiere, 

Hadrien Reyre, Ludovic Liege, Nicholas D 

Moore, Bernard Begaud. (France) 

52 Graphs in Pharmacoepidemiology - Can 

They Be Improved? [564] 

Charles H Goldsmith. (Canada) 

53 A Review of Systematic Reviews in 

Postmarketing Drug Safety [565] 

Jose G Orozco-Diaz, Howard Schachter, David 

Moher, Vicky Hogan, Connie Barrowclough, 

Ariel E Arias. (Canada) 

54 Confounding Bias Due to Subject 

Withdrawals in a Randomized Controlled 

Trial with an Intent-To-Treat Analysis [566] 

H Michael Arrighi, David A Brown. 


55 Effects of Cyclooxygenase-2 Selective 

Inhibitors, Rofecoxib and Celecoxib, and of 

NSAIDs on Esophageal Cancer [567] 

Marc Y Bardou, Alan N Barkun, Joumana 

Ghosn, Marie Hudson, Elham Rahme. (France) 

57 Coxibs: Evolution of Prescription’s 

Behaviour in France [569] 

Julie Biga, Florence Taboulet, Maryse Lapeyre- 

Mestre, Robert Bourrel, Jean-Louis Montastruc. 


58 Methodological and Logistical Aspects of 

the Cadeus (Cox-2 and NSAIDs Description 

of Users) Study [570] 

Fanny Depont, Annie Fourrier-Reglat, Cecile 

Droz, Michel Amouretti, Yvon Merliere, Pierre 

Fender, Patrick Blin, Bernard Begaud, 

Nicholas Moore. (France) 

59 Risk of Acute Cardiac Events among 

Patients Treated with Cyclooxygenase-2 

Selective and Non-Selective Nonsteroidal 

Antiinflammatory Drugs [571] 

David J Graham, David Campen, Craig 

Cheetham, Rita Hui, Michele Spence, 

Wayne A Ray. (United States) 

60 Upper Gastrointestinal Adverse Drug 

Reactions and Selective Cyclo-Oxygenase-2 

Inhibitors (Celecoxib and Rofecoxib): A 

Case / Non-Case Study in the French 

Pharmacovigilance Database [572] 

Stephanie S Lugardon, Maryse Lapeyre- 

Mestre, Jean-Louis Montastruc. (France) 

61 Costs of Coxibs, Nonselective Nsaids and 

Concomitant Gastroprotective Agents among 

Patients Covered by the Régime Général 

D’assurance-MéDicaments in Quebec [573] 

Elham Rahme, Isabelle Chabot, Youssef 

Toubouti, Jacques LeLorier. (Canada) 

62 Therapy Switching and Associated Costs in 

Patients on Selective Cox-2 Inhibitors and 

Nonselective NSAIDs in an Elderly 

Population in Quebec, Canada [574] 

Elham Rahme, Youssef Toubouti, Elke 

Hunsche, Isabelle Chabot. (Canada) 

63 Gastrointestinal Safety and Vioxx 

Effectiveness in Patients at High Risk for 

Gastric Injury [575] 

Stephane Bissonnette, Emmanuelle Denis, 

Yola Moride, John Sampalis. (Canada) 

64 Use of Selective Cox-Inhibitors in High Risk 

Patients: Possible Effect of Reimbursement 

on Adverse Events [576] 

Steinar Madsen, Stian Bjerke, Harald 

Liselvand, Pernille Harg. (Norway) 

65 Prospective Analysis of GP Database: 

Comparing Treatments Following First 

Consultation for a Symptomatic Hip or Knee 

in Elderly People [577] 

Louise Linsell, Mary Thompson, Jill Dawson, 

Krina Zondervan, Peter Rose, Tony Randall, 

Andrew Carr, Ray Fitzpatrick. (United Kingdom) 

66 Effectiveness of Lipid-Lowering Therapy in 

Primary Care in France [578] 

Eric Van Ganse, Michel Bertrand, Philippe Moulin, 

Thierry Souchet, Gerard de Pouvourville. (France) 

56 Are Cox-2 Selective Inhibitors Preferentially 67 Cost-Effectiveness Analysis of Escitalopram 

Prescribed in Patients on Aspirin Therapy? 

in the Treatment of Major Depressive 

[568] 

Disorder in Austria [579] 

Mary Teeling, Kathleen Bennett, John Feely. 

Michiel EH Hemels, Siegfried Kasper, Evelyn 

(Ireland) 

Walter, Thomas R Einarson. (France) 


& Therapeutic Risk Management 

68 Cost-Effectiveness of Nesiritide Versus 

Dobutamine in Patients with Acutely 

Decompensated Heart Failure [580] 

Tobias Gerhard, Issam Zineh, Abraham G 

Hartzema, Almut G Winterstein. (United States) 

69 Predictors of Thirst and Interdialytic Weight 

Gain in Hemodialysis Patients: A Cross- 

Sectional Analysis [581] 

Shih-Chen Kuo, Junne-Ming Sung, Yea-Huei 

Yang Kao, How-Ran Guo, Szu-Yuan Lee, Jeng- 

Jong Huang. (Taiwan) 

70 Cost-Effectiveness of Screening Albuminuria 

Subsequent Treatment with Fosinopril To 

Prevent Cardiovascular Events. Pharmacoeconomic 

Analysis for Prevend-It [582] 

Jarir Atthobari, Folkert W Asselbergs, Paul E 

de Jong, Lolkje TW de Jong van den Berg, 

Maarten J Postma. (Netherlands) 

71 Mechanical and Allergic Adverse Events 

Related to Central Vascular Catheters: 

Epidemiology in the Medicare In-Hospital 

Surgical Population, 2002 [583] 

Roselie A Bright, Leonard Mermel, Chesley 

Richards, Deborah Yoder. (United States) 

72 Survey of Medical Healthcare Resource Use 

in Ambulatory Patients with Parkinson’s 

Disease [584] 

Marco Cosentino, Emilia Martignoni, Donatella 

Michielotto, Daniela Calandrella, Giulio 

Riboldazzi, Claudio Pacchetti, Sergio Lecchini, 

Giuseppe Nappi, Gianmario Frigo. (Italy) 

73 Fibromyalgia: Survey of Global 

Fibromyalgia Management by French 

General Practitioners in 2003 [585] 

Francis Blotman, Eric Thomas, Eric Myon, 

Yves Mainguy, Charles Taieb. (France) 

74 Fibromyalgia: Survey of Global 

Fibromyalgia Management by French 

Rheumatologists in 2003 [586] 


Jean Paul Caubere, Charles Taieb. (France) 

75 Fibromyalgia: Cross-Survey of Rheumatologists 

and General Practitioners Awareness and 

Knowledge of Fibromyalgia [587] 


Etienne Andre, Charles Taieb. (France) 

76 Adverse Drug Reactions in Patients from a 

Defined Cohort of Elderly Admitted to an 

Emergency Ward [588] 

Anders Helldén, Maria Johansson, Mia von 

Euler, Lars Axelsson, Gunnar Öhlén, 

Bo Herrlin, Ulf Bergman. (Sweden) 

77 Epidemiology of Osteoporosis in the 

Netherlands (1993-2002) [589] 

Martien JM Panneman, Wim G Goettsch, Piotr 

Kramarz, Ron MC Herings. (Netherlands) 

78 Fibromyalgia Syndrom: A French 

Epidemiological Survey [590] 

Charles Taieb, Jean Paul Caubere, Yves 

Mainguy, Etienne Andre, Eric Myon. (France) 

79 Fibromyalgia: A Socio-Demographic Profile 

of Patients Suffering from Fibromyalgia in 

France [591] 

Charles Taieb, Yves Mainguy, Jean Paul 

Caubere, Etienne Andre, Eric Myon. (France)


80 A Registry-Based Study of Incidence of 

Hospitalisation for Interstitial Lung Disease 

(ILD) among Non Small Cell Lung Cancer 

(NSCLC) Patients in Sweden [592] 

Fredrik Nyberg, Anna Bergström, Saga 

Johansson, Göran Pershagen. (Sweden) 

81 A Registry-Based Study of the Incidence of 

Hospitalisation for Diverse Comorbidities 

among Non Small Cell Lung Cancer (Nsclc) 

Patients in Sweden [593] 

Fredrik Nyberg, Anna Bergström, Saga 

Johansson, Göran Pershagen. (Sweden) 

82 Fibromyalgia: Survey of GPs Awareness and 

Knowledge of FMS [594] 

Francis Blotlman, Eric Myon, Eric Thomas, 

Etienne Andre, Charles Taieb. (France) 

83 Fibromyalgia: Survey of Rheumatologists 

Awareness and Knowledge of Fibromyalgia 

[595] 

Francis Blotman, Eric Myon, Jean Paul 

Caubere, Eric Thomas, Charles Taieb. (France) 

84 Economic Evaluation of Primary Prevention 

of CVD Events with Statins [596] 

Silvia Bustacchini, Lorenzo G Mantovani, 

Pierfrancesco Ruffo, Desiree Bastarolo, 

Alessandro Battaggia, Mario Celebrano, Guido 

Danti, Sandro Girotto, Giuseppe Lombardo, 

Luigi Mezzalira, Verona Collaborative Study 

Group. (Italy) 

85 A Cross-Sectional Survey To Evaluate the 

Profile of Cardiovascular Risk in the 

Population: The Verona Collaborative 

Study [597] 

Silvia Bustacchini, Alessandro Battaggia, 

Gianstefano Blengio, Mario Celebrano, Guido 

Danti, Sandro Girotto, Roberta Joppi, Giuseppe 

Lombardo, Mersia Mirandola, Pierfrancesco 

Ruffo, Verona Collaborative Study Group. (Italy) 

86 Estimating the Reduction in Employee 

Disability Days by Modifying Cardiovascular 

Risk Factors: Developing a Markov Model [598] 

Louis Coupal, Steven Grover, Hanna Zowall, 

Jean-Eric Tarride. (Canada) 

87 A Meta-Analysis of Cancer Risk and Asthma 

Status Fails To Demonstrate an Association 

[599] 

Pat Tennis, Beth Sherrill, Carlos Fernandez, 

Evelyn Rodriguez. (United States) 

88 Increased Rates of Diagnosis for 

Hypertension or Dyslipidaemia in Patients 

Previously Identified with One of These Risk 

Factors: Data from the United Kingdom [600] 

Thomas M MacDonald, Steve V Morant, Essy 

Mozaffari. (United Kingdom) 

89 Changes in Hypokalemia and Hyperkalemia 

Prevalence between 1991 and 2000 in the 

US According to Hypertensive Status and 

Treatment [601] 

Andrew Maguire, Maria del Mar Melero- 

Montes, Isabel Saez-Lloret, Cristina Varas- 

Lorenzo, Susana Perez-Gutthann. (Spain) 

90 A Retrospective Cohort Study of Diabetes 

Mellitus and Antipsychotic Treatment in the 

UK [602] 

Patrizia Cavazzoni, Kenneth Hornbuckle, 

Christopher Carlson, Frank DeLisle, Rebecca 

Noel, Alan Breier. (United States) 

91 Tertiary Use of Pharmacoepidemiology 

Methods for Surveillance of Emerging 

Disease Outbreaks [603] 

Andy Stergachis, Bryant T Karras, Joe Fazio. 


92 Incidence of Non Hodgkins Lymphoma 

among Patients Exposed to Hepatitis B 

Virus [604] 

Marianne Ulcickas Yood, Charles Quesenberry, 

Jr., Dianlin Guo, Cary Caldwell, Karen Wells, 

Jun Shan, Gena Kucera, Mary Lou Skovron. 


93 Mean Preferences for Barthel Index Disability 

States in a Community Sample [605] 

Jamie Banks, Maribel Salas, Ann Netten. 


94 Utility in Patients with Stroke Related 

Disability [606] 

Sooyeon Kwon, Pamela W Duncan, Abraham 

G Hartzema, Sue-MIn Lai. (United States) 

95 Estimating Annual Prevalence of Clinically- 

Significant Psoriasis in the General Practice 

Research Database (GPRD) [607] 

Martin M Crane, Jean M Hastie, Carla L Black. 


96 Clustering or Undue Association of Raised 

Blood Pressure and Blood Cholesterol in the 

Who Monica Project Population Surveys 

1989-97 [608] 

Hugh Tunstall-Pedoe, Ruoling Chen, for the 

WHO MONICA Project. (United Kingdom) 

97 Prevalence of Individuals with Both Raised 

Blood Pressure and Raised Cholesterol in 

Who Monica Project Population Surveys 

1989-97 [609] 

Hugh Tunstall-Pedoe, Ruoling Chen, Piotr 

Kramarz, for the WHO MONICA Project. 


98 Falls and Overactive Bladder: The Need for 

a Prevention Strategy [610] 

Robert Freeman, Sarah M Bridge, Julie Ann 

Dooley. (United Kingdom) 

99 Natural History of Chest Pain in General 

Practice Setting [611] 

Ana Ruigomez, Saga Johansson, Mari-Ann 

Wallander, Luis A Garcia Rodriguez. (Sweden) 

100 Natural History of Dyspepsia in General 

Practice: Incidence, Comorbidity and Risk 

Factors [612] 

Ana Ruigomez, Mari-Ann Wallander, Saga 

Johansson, Luis A Garcia Rodriguez. (Sweden) 

101 Alcohol and the Risk of Colorectal Cancer 

in the Korean Elderly: A Cohort Study [613] 

Hoi-Jeong Lim, Byung-Joo Park. 

(Republic of Korea) 

102 Quantitative Analysis of Class 1 Drug 

Reimbursement Submissions in Belgium [614] 

Philippe B Van Wilder, Gert A Verpooten, Jean 

Paul Degaute, Hugo Robays, Francis Arickx, 

Alain G Dupont. (Belgium) 

103 Rapid Monitoring of Drug Discontinuation 

Rates in Response to Restrictions in Drug 

Reimbursement [615] 

Colin R Dormuth, Sebastian Schneeweiss. 


104 An Economic Model To Assess the Cost 

Effectiveness of Treating Asthmatics with 

Gastroesophageal Disease [616] 

Harry B Nyanteh, Cameron K Schiller, Sonya 

Sednecor, Abraham Hartzema. (United States) 

105 Clinical and Economic Burden of Comorbid 

Hypertension and Dyslipidemia in the 

United States [617] 

Joshua S Benner, Allison A Petrilla, David S 

Battleman. (United States) 

106 The Social Need for New Drugs and the 

Pharmaceutical Market in 2003 [618] 

Carlos CF Vidotti, Lia LC Castro, Mariana HM 

Cunha. (Brazil) 

107 Comparison of 2 Methods for Capturing 

Drug Utilisation Data in Belgium [619] 

Philippe B Van Wilder, Andre De Swaef, Gert 

A Verpooten. (Belgium) 

108 Change in Prescribing Patterns of Hormone 

Replacement Therapy (HRT) Following the 

Publication of the Women’s Health 

Initiative Study (WHI) [620] 

Briegeen G Girvin, Therese M Rafferty, 

Michael R Stevenson, Dennis G Johnston. 


109 Clinical Background of Women Prescribed 

Tibolone or Combined Estrogen + 

Progestogen Therapies (CEPT): A UK 

MEDIPLUS® Study [621] 

Erica JM Velthuis-te Wierik, Paul T Hendricks, 

Mariette Boerstoel-Streefland. (Netherlands) 

110 A Population-Based Study of the 

Effectiveness of Antiresorptive Agents on 

Risk Reduction of Fracture [622] 

Sylvie Perreault, Alice E Dragomir, Lucie 

Blais, Yola Moride, Michel Rossignol, Louis- 

Georges Ste-Marie, Julio Fernandes. (Canada) 

111 Chronic Venous Disease: Care Impact [623] 

Jean Jerome Guex, Eric Myon, Charles Taieb. 

(France) 

112 Chronic Venous Disease: Compliance with 

Treatment [624] 


(France) 

113 Chronic Venous Disease: Disease Age 

Impact [625] 


(France) 

114 Chronic Venous Disease: Through Body 

Mass Index [626] 

Jean Jerome Guex, Charles Taieb, Eric Myon. 

(France) 


✒


115 Chronic Venous Disease: Patients Profile [627] 

Jean Jerome Guex, Charles Taieb, Eric Myon. 

(France) 

116 Chronic Venous Disease and Health Status 

[628] 


(France) 

117 Chronic Venous Disease and Specific 

Quality of Life [629] 


(France) 

118 Chronic Venous Disease and Depressive 

Symptomatology [630] 


(France) 

119 Postmarketing Surveillance of Severe 

Hematological Reactions to Drugs (Aplastic 

Anemia and Agranulocytosis): Potential 

Utility of an Empirical Bayesian Signal 

Detection Algorithm [631] 

Manfred Hauben, Lester Reich. (United States) 

120 Endotoxin-Like Reactions with Intravenous 

Gentamicin: Results from and Empirical 

Bayesian Data Mining Signal Detection 

Algorithm [632] 


121 Pancreatitis Reports with Atypical 

Antipsychotics: Retrospective Application of 

an Empirical Bayesian Statistical Signal 

Detection Algorithm [633] 


122 Postmarketing Surveillance of Severe 

Cutaneous Reactions to Drugs (Stevens 

Johnson Syndrome and Toxic Epidermal 

Necrolysis): Potential Utility of an Empirical 

Bayesian Signal Detection Algorithm [634] 


123 Adverse Events in Black-Box Warnings: 

Retrospective Application of an Empirical 

Bayesian Screening Algorithm [635] 


124 Safety Related Drug-Labeling Changes: 

Findings from Two Signal Detection 

Algorithms [636] 


125 Postmarketing Surveillance of Potentially 

Fatal Reactions to Oncology Drugs; Potential 

Utility of an Empirical Bayesian Signal 

Detection Algorithm To Drug Classes Likely 

To Qualify for Accelerated Approval and That 

Have a High Degree of Off-Label Use [637] 


126 Understanding the Role of the Report Date 

in Signal Detection Analyses [638] 

Matthew W Reynolds, Susan D Ross, Kyle 

Fahrbach, Diana Frame, Catherine Cella. 


127 Understanding the Role of the Report 

Source in Signal Detection Analyses [639] 

Matthew W Reynolds, Susan D Ross, Kyle 

Fahrbach, Diana Frame, Kimberly James. 


128 Pattern Detection for Celecoxib and 

Rofexcoib in the WHO Database [640] 

Andrew Bate, Niklas Noren, Roland Orre, 

Marie Lindquist, Ralph Edwards. (Sweden) 

129 Impact Analysis of Signals Detected from 

Spontaneous Adverse Reaction Reporting 

Data [641] 

Patrick C Waller, Emma L Heeley, Jane NS 

Moseley. (United Kingdom) 

130 Testing and Implementing Signal Impact 

Analysis in a Regulatory Setting: Results of 

a Pilot Study [642] 

Emma L Heeley, Patrick C Waller, Jane NS 

Moseley. (United Kingdom) 

131 Choosing the Measure of Relative 

Proportional Reporting in Quantitative 

Analyses of Spontaneous Reports [643] 

Alejandro Arana, Félix Arellano, David Sánchez- 

Matienzo, Susana Pérez-Gutthann. (Spain) 

132 The Impact of Grouping Drugs by ATC 

Codes on Detecting a Signal from Japanese 

Spontaneous Reports [644] 

Yukari Kamijima, Eri Kawabe, Noriko Kubota, 

Tsugumichi Sato, Kiyoshi Kubota. (Japan) 

133 The European Active Surveillance Study on 

HRT Prescribing Practice, Benefits and 

Safety (EURAS) [645] 

Anita Assmann, Lothar AJ Heinemann. 

(Germany) 

134 Strategies To Recruit Women to an HRT 

Study Post Women’s Health Initiative: [italic]The 

Women’s Health and Hormone Study 

Experience[/italic] [646] 

Ilona Csizmadi, Linda S Cook, Christine M 

Friedenreich, Heather E Bryant, Gordon Fick, 

Anthony M Magliocco, Michael Pollak. (Canada) 

135 Prevalence and Costs of Difficult-To-Treat 

Depression in a Canadian Claims Database 

[647] 

Alki N Burdett, Charlotte C Gard, Christopher 

J Longo, David P Miller. (United States) 

136 Use of Nutritional Supplements and the 

Dietary Practices of a Group of South 

African Students: A Preliminary Study [648] 


137 Vasculitis Associated with Drug Use in 

Children in Italy [649] 

Giuseppe Traversa, Francesca Menniti- 

Ippolito, Roberto Da Cas, Liviana Da Dalt, 

Elisabetta Bressan, Carla Morando, Elena 

Falcon, Rossella Rossi, Paola Barabino, 

Salvatore Renna. (Italy) 

138 Cancer Risk among Users of Statins: A 

Population-Based Cohort Study [650] 

Soren Friis, Aslak H Poulsen, Soren P 

Johnsen, Joseph K McLaughlin, Henrik T 

Sorensen, Jorgen H Olsen. (Denmark) 

139 An Economic Analysis of the Impact of 

Highly Active Antiretroviral Therapy 

(HAART) Associated Dyslipidemia on 

Cardiovascular Risk and Life Expectancy [651] 

Steven Grover, Louis Coupal, Ilka 

Lowensteyn, Sylvie Marchand, Mohammed 

Kaouache, Hanna Zowall, Jayanti Mukherjee, 

Uchenna Iloeje. (Canada) 

140 FDA Adverse Event Reports on Statin- 

Associated Peripheral Neuropathy [652] 

Homa B Dastani, Jim Wilson. (United States) 

141 Adherence to Antiretroviral Therapy (HAART) 

in the Province of Quebec, Canada [653] 

Marc Dorais, Richard G Lalonde, Mariana 

Maier-Moldovan, Jacques LeLorier. (Canada) 

142 A Cohort of Cholinesterase Inhibitors 

(CHEI) USERS in the Province of Quebec, 

Canada [654] 

Marc Dorais, Fadi Massoud, Benedict 

Lescrauwaet, Frederic Lavoie, Jacques 

LeLorier. (Canada) 

143 What Do We Show and Who Does So? An 

Analysis of the Abstracts Presented at the 

19th ICPE [655] 

Alejandro Arana, Elena Rivero, Toine CG 

Egberts. (Spain) 

144 A Literature Review on the Brazilian 

Published Output on Pharmaceutical Care 

in the past Five Years (1999-2003) [656] 

Maria Lourdes Oshiro, Lia Lusitana Cardozo 

de Castro. (Brazil) 

145 Compliance with Anti-Hypertensive Drugs 

through the Use of Reminder Cards [657] 

Jose P Guerreiro, Filipa Costa, Brenda 

Madureira, Ana C Miranda. (Portugal) 

146 Study of Adherence to Treatment Evaluated 

by the Doctor and Self-Reported by the 

Patient [658] 

Guitton Emmanuelle, Trenado Emmanuel, 


147 The Association between Ovarian Cancer 

and Hormone Replacement Therapy: A 

Case-Control Study amongst Postmenopausal 

Women in UK Primary Care [659] 

Corinne S de Vries, Annie Hutchison, Richard 

DT Farmer. (United Kingdom) 

148 Comparative Assessment of Four Drug 

Interaction Databases [660] 

Agnes I Vitry. (Australia) 

149 The Risk of First Seizure Associated with 

Mefenamic Acid in Women of Reproductive 

Age [661] 

Daniel I Mines, Laura A Novelli. 


END - Session C 

42

ISPE Bordeaux Final CR/Bladen - International Society for ...

Create successful ePaper yourself

Delete template?

Save as template?